{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "210a31c3-bddf-4db9-a61f-f7a380a68346",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Out[1]: [FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2023/', name='clinicaltrial_2023/', size=0, modificationTime=0),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2023-1.zip', name='clinicaltrial_2023-1.zip', size=57166668, modificationTime=1713832661000),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2023.csv', name='clinicaltrial_2023.csv', size=292436366, modificationTime=1714269234000),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2023.zip', name='clinicaltrial_2023.zip', size=57166668, modificationTime=1712589310000),\n FileInfo(path='dbfs:/FileStore/tables/pharma-1.zip', name='pharma-1.zip', size=109982, modificationTime=1713832611000),\n FileInfo(path='dbfs:/FileStore/tables/pharma.csv/', name='pharma.csv/', size=0, modificationTime=0),\n FileInfo(path='dbfs:/FileStore/tables/pharma.zip', name='pharma.zip', size=109982, modificationTime=1712589332000),\n FileInfo(path='dbfs:/FileStore/tables/steam_200k-1.csv', name='steam_200k-1.csv', size=8059447, modificationTime=1714157236000),\n FileInfo(path='dbfs:/FileStore/tables/steam_200k-2.csv', name='steam_200k-2.csv', size=8059447, modificationTime=1714337658000),\n FileInfo(path='dbfs:/FileStore/tables/steam_200k.csv', name='steam_200k.csv', size=8059447, modificationTime=1713124868000)]"
     ]
    }
   ],
   "source": [
    "dbutils.fs.ls(\"/FileStore/tables/\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "db13de35-b7ff-4552-b992-86f772ddc58b",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Out[2]: True"
     ]
    }
   ],
   "source": [
    "dbutils.fs.cp(\"/FileStore/tables/clinicaltrial_2023.zip\", \"file:/tmp/\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "d38a8dd8-d260-4514-9c20-14b8c2b7615b",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Rserv\nRtmp1EUY0n\nchauffeur-daemon-params\nchauffeur-daemon.pid\nchauffeur-env.sh\nclinicaltrial_2023.zip\ncustom-spark.conf\ndriver-daemon-params\ndriver-daemon.pid\ndriver-env.sh\nhsperfdata_root\npython_lsp_logs\nsystemd-private-cd7aa280e67e429f85a0ae2cca21a4dc-apache2.service-MUpfHg\nsystemd-private-cd7aa280e67e429f85a0ae2cca21a4dc-ntp.service-yxq2vh\nsystemd-private-cd7aa280e67e429f85a0ae2cca21a4dc-systemd-logind.service-QqVD6g\nsystemd-private-cd7aa280e67e429f85a0ae2cca21a4dc-systemd-resolved.service-0WSoAf\ntmp.jT9xtZh66L\n"
     ]
    }
   ],
   "source": [
    "%sh\n",
    "ls /tmp/"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "6b69851f-33ab-4659-9285-023ce21dc6a1",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Archive:  /tmp/clinicaltrial_2023.zip\n  inflating: /tmp/clinicaltrial_2023.csv  \n"
     ]
    }
   ],
   "source": [
    "%sh\n",
    "unzip -d /tmp/ /tmp/clinicaltrial_2023.zip"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "72e5645b-7980-411a-86af-621020ee2675",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "/tmp/clinicaltrial_2023.csv\n"
     ]
    }
   ],
   "source": [
    "%sh\n",
    "ls /tmp/clinicaltrial_2023.csv"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "aaca02fb-75e8-4217-aac4-5eeca082b604",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Out[6]: True"
     ]
    }
   ],
   "source": [
    "dbutils.fs.mv(\"file:/tmp/clinicaltrial_2023.csv\", \"/FileStore/tables/clinicaltrial_2023.csv\", True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "0d03a05f-443e-4b71-920b-a8d2a05591fa",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Out[7]: [FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2023.csv', name='clinicaltrial_2023.csv', size=292436366, modificationTime=1714515227000)]"
     ]
    }
   ],
   "source": [
    "dbutils.fs.ls(\"FileStore/tables/clinicaltrial_2023.csv/\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "1a2c8f69-7883-45ec-bf48-d4481ed46cc8",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[Truncated to first 65536 bytes]\nOut[8]: '\"Id\\tStudy Title\\tAcronym\\tStatus\\tConditions\\tInterventions\\tSponsor\\tCollaborators\\tEnrollment\\tFunder Type\\tType\\tStudy Design\\tStart\\tCompletion\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT03630471\\tEffectiveness of a Problem-solving Intervention for Common Adolescent Mental Health Problems in India\\tPRIDE\\tCOMPLETED\\tMental Health Issue (E.G.\", Depression, Psychosis, Personality Disorder,\" Substance Abuse)\\tBEHAVIORAL: PRIDE \\'Step 1\\' problem-solving intervention|BEHAVIORAL: Enhanced usual care\\tSangath\\tHarvard Medical School (HMS and HSDM)|London School of Hygiene and Tropical Medicine\\t250.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT\\t2018-08-20\\t2019-02-28\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT05992571\\tOral Ketone Monoester Supplementation and Resting-state Brain Connectivity\\t\\tRECRUITING\\tCerebrovascular Function|Cognition\\tOTHER: Placebo|DIETARY_SUPPLEMENT: β-OHB\\tMcMaster University\\tAlzheimer\\'s Society of Brant\", Haldimand Norfolk,\" Hamilton Halton\\t30.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE\\t2023-10-25\\t2024-08\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT00237471\\tImpact of Tight Glycaemic Control in Acute Myocardial Infarction\\t\\tTERMINATED\\tMyocardial Infarct|Hyperglycemia\\tDRUG: Insulin (tight blood glucose control)\\tMelbourne Health\\tNational Health and Medical Research Council\",\" Australia|Bristol-Myers Squibb\\t40.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT\\t2005-10\\t2006-05\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT03820271\\tNew Prognostic Predictive Models of Mortality of Decompensated Cirrhotic Patients Waiting for Liver Transplantation\\tSUPERMELD\\tRECRUITING\\tDecompensated Cirrhosis|Liver Transplantation\\tOTHER: SuperMELD\\tAssistance Publique - Hôpitaux de Paris\\t\\t500.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER\\t2020-10-01\\t2023-10-01\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT06229171\\tInTake Care: Development and Validation of an Innovative\",\" Personalized Digital Health Solution for Medication Adherence Support in Cardiovascular Prevention\\tInTakeCare\\tNOT_YET_RECRUITING\\tHypertension|Treatment Adherence and Compliance|Digital Health\\tOTHER: adherence support system based on a vocal assistant\\tIstituto Auxologico Italiano\\tIstituti Clinici Scientifici Maugeri SpA|Politecnico di Milano\\t206.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER\\t2024-10-01\\t2026-04-01\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02945371\\tTailored Inhibitory Control Training to Reverse EA-linked Deficits in Mid-life\\tREV\\tCOMPLETED\\tSmoking|Alcohol Drinking|Prescription Drug Abuse|Substance-Related Disorders|Oral Intake Reduced\\tBEHAVIORAL: Person-centered inhibitory control training|BEHAVIORAL: Active behavioral response training\\tUniversity of Oregon\\t\\t103.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION\\t2014-09\\t2016-05\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT01055171\\tNeuromodulation of Trauma Memories in PTSD & Alcohol Dependence\\t\\tCOMPLETED\\tAlcohol Dependence|PTSD\\tDRUG: Propranolol|DRUG: Placebo\\tMedical University of South Carolina\\tNational Institute on Alcohol Abuse and Alcoholism (NIAAA)\\t44.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT\\t2010-01\\t2012-08\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT01125371\\tComputerized Brief Alcohol Intervention (BI) for Binge Drinking HIV At-Risk and Infected Women\\t\\tCOMPLETED\\tAlcohol; Harmful Use|Binge Drinking|Risk Behavior|HIV Infection\\tBEHAVIORAL: Computerized brief alcohol intervention + IVR booster calls|BEHAVIORAL: Computerized brief alcohol intervention|BEHAVIORAL: Attention Control\\tJohns Hopkins University\\tNational Institute on Alcohol Abuse and Alcoholism (NIAAA)\\t439.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT\\t2011-10\\t2016-06-07\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02554071\\tManitoba Pharmacist Initiated Smoking Cessation Pilot Project\\t\\tCOMPLETED\\tSmoking Cessation\\tOTHER: Pharmacist - Smoking Cessation Support\\tUniversity of Manitoba\\tGovenment of Manitoba|Canadian Foundation for Pharmacy|Neighbourhood Pharmacy Association of Canada\\t119.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE\\t2014-01\\t2014-11\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT01772771\\tMolecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program\\t\\tRECRUITING\\tGlioma|Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm|Melanoma|Sarcoma\\tPROCEDURE: Biospecimen Collection|OTHER: Genetic Testing|OTHER: Medical Chart Review\\tM.D. Anderson Cancer Center\\tNational Cancer Institute (NCI)\\t12000.0\\tOTHER\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2012-03-01\\t2033-03-01\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02633371\\tA Pilot Study Exploring the Efficacy and Safety of Topical Oxybutynin 3% Gel for Primary Focal Hyperhidrosis in Adolescents and Young Adults\\t\\tCOMPLETED\\tHyperhidrosis\\tDRUG: Oxybutynin 3% gel\\tUniversity of Colorado\",\" Denver\\tSociety for Pediatric Dermatology\\t10.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT\\t2016-02\\t2017-05\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT03400371\\tBiology of Juvenile Myoclonic Epilepsy\\tBIOJUME\\tRECRUITING\\tJuvenile Myoclonic Epilepsy\\tOTHER: Blood draw|OTHER: Existing samples\\tKing\\'s College London\\tKing\\'s College Hospital NHS Trust|Charles University\",\" Czech Republic|Hopital Universitaire Robert-Debre|Vestre Viken Hospital Trust|The Hospital for Sick Children|Cardiff University|Odense University Hospital\\t1000.0\\tOTHER\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2017-07-13\\t2026-06-30\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT00120471\\tSafety and Blood Levels of Tenofovir Disoproxil Fumarate in HIV Infected Pregnant Women and Their Babies\\t\\tCOMPLETED\\tHIV Infections\\tDRUG: Tenofovir disoproxil fumarate|DRUG: Tenofovir disoproxil fumarate|DRUG: Tenofovir disoproxil fumarate\\tNational Institute of Allergy and Infectious Diseases (NIAID)\\tEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute on Drug Abuse (NIDA)|National Institute of Mental Health (NIMH)\\t122.0\\tNIH\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION\\t2006-11\\t2011-12\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04784871\\tPromoting Wellbeing: The Five Ways to All Intervention\\t5WaysA\\tCOMPLETED\\tWellbeing|Health Attitude|Quality of Life\\tBEHAVIORAL: 5waysA Intervention|BEHAVIORAL: 5waysA Active wait-list control|BEHAVIORAL: 5waysA Inactive wait-list control\\tUniversity of Oslo\\tNorwegian Institute of Public Health|Norwegian Council for Mental Health|The Dam Foundation\\t970.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION\\t2021-03-04\\t2023-02-24\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02383771\\tReversal of the Anti-platelet Effects of Ticagrelor\\tREVERSAL\\tCOMPLETED\\tCoronary Artery Disease\\tDRUG: Ticagrelor|DRUG: Aspirin + Ticagrelor|DRUG: Control|DRUG: Aspirin + Ticagrelor\\tThe First Affiliated Hospital with Nanjing Medical University\\tNational Natural Science Foundation of China\\t64.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT\\t2015-03\\t2016-12\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT03269071\\tNeural Stem Cell Transplantation in Multiple Sclerosis Patients\\tSTEMS\\tCOMPLETED\\tProgressive Multiple Sclerosis\\tDRUG: human fetal-derived Neural Stem Cells (hNSCs)\\tIRCCS San Raffaele\\tFondazione Italiana Sclerosi Multipla\\t4.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT\\t2017-05-17\\t2021-07-31\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT01659671\\tRCT of the Effect of Uvulopalatopharyngoplasty Compared to Expectancy in Patients With Obstructive Sleep Apnea\\tSKUP3\\tCOMPLETED\\tObstructive Sleep Apnea Syndrome\\tPROCEDURE: Uvulopalatopharyngoplasty\\tKarolinska University Hospital\\tKarolinska Institutet\\t65.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT\\t2007-06\\t2014-05\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04765371\\tComparison Between Prednisolone and Dexamethasone on Mortality in Patients on Oxygen Therapy\",\" With CoViD-19\\tCOPreDex\\tCOMPLETED\\tCoronavirus Infection\\tDRUG: DEXAMETHASONE|DRUG: PREDNISOLONE\\tHôpital NOVO\\t\\t89.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT\\t2021-03-03\\t2022-05-13\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02830971\\tDeveloping a Standardized Learning Curve\\t\\tCOMPLETED\\tRegistered Nurses|Nursing Personnel|Motor Skills\\tPROCEDURE: Doing Different ICU techniques and skills\\tBaqiyatallah Medical Sciences University\\tShahid Beheshti University|Tehran University of Medical Sciences\\t60.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE\\t2016-07\\t2021-04-12\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT00416871\\tInterleukin-2 and Interferon in Treating Patients With Metastatic Kidney Cancer\\t\\tCOMPLETED\\tKidney Cancer\\tBIOLOGICAL: aldesleukin|BIOLOGICAL: recombinant interferon alfa\\tCentre Leon Berard\\t\\t220.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: |Masking: NONE|Primary Purpose: TREATMENT\\t\\t2006-02\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT05900271\\tDutch-Depression Outcome Trial Comparing 5 Day Multi Daily Neuronavigated Theta Burst Sessions With 6 Weeks rTMS\\tDDOT\\tACTIVE_NOT_RECRUITING\\tTreatment Resistant Depression\\tDEVICE: rTMS|DEVICE: iTBS\\tAmsterdam UMC\",\" location VUmc\\tRadboud University Medical Center|University Medical Center Groningen|Maastricht University|Trimbos|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)\\t108.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT\\t2023-11-15\\t2027-12\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02469571\\tModulation of Gut Microbiota in Early Sepsis: A Pilot Study\\tMGM-sepsis\\tCOMPLETED\\tSepsis\\tDIETARY_SUPPLEMENT: Winclove 607|DIETARY_SUPPLEMENT: Placebo\\tMedical University of Graz\\t\\t15.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION\\t2015-09-01\\t2018-03-01\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT05807971\\tAssessment of Safety\", Tolerability, Pharmacokinetics,\" and Pharmacodynamics of ATH-063 in Healthy Subjects\\t\\tRECRUITING\\tInflammatory Bowel Diseases|Crohn Disease|Ulcerative Colitis|Autoimmune Diseases\\tDRUG: ATH-063|DRUG: Placebo\\tAthos Therapeutics Inc\\tSyneos Health|Athos Therapeutics Australia Pty Ltd\\t76.0\\tINDUSTRY\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT\\t2023-04-06\\t2024-02-08\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02083471\\tCow\\'s Milk and Hen\\'s Egg Hyposensitization in Adults\\t\\tUNKNOWN\\tEgg Allergy|Cow\\'s Milk Allergy\\tDIETARY_SUPPLEMENT: Specific Oral Tolerance Induction with Egg or Cow\\'s milk\\tTurku University Hospital\\t\\t40.0\\tOTHER_GOV\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT\\t2015-04\\t2017-05\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT01062971\\tClinical Study of A Fixed Combination of Timolol-Brimonidine-Dorzolamide\\t\\tCOMPLETED\\tPrimary Open Angle Glaucoma|Ocular Hypertension\\tDRUG: dorzolamide-timolol-brimonidine\\tLaboratorios Sophia S.A de C.V.\\t\\t124.0\\tINDUSTRY\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT\\t2006-02\\t2008-06\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT03928171\\tThe Effect of Intra-abdominal Pressure on Peritoneal Perfusion During Laparoscopic Colorectal Surgery\\tPERFUSION\\tCOMPLETED\\tLaparoscopic Surgery|Pneumoperitoneum\\tOTHER: Intra-abdominal pressure during laparoscopy\\tRadboud University Medical Center\\t\\t30.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT\\t2018-06-13\\t2018-12-24\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT00897871\\tEvaluating the Side Effects and How Well Anticancer Drugs Work in Very Young Patients With Cancer\\t\\tUNKNOWN\\tUnspecified Childhood Solid Tumor\",\" Protocol Specific\\tDRUG: carboplatin|DRUG: cyclophosphamide|DRUG: etoposide phosphate|GENETIC: gene expression analysis|GENETIC: polymorphism analysis|OTHER: pharmacological study\\tChildren\\'s Cancer and Leukaemia Group\\t\\t60.0\\tOTHER\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2007-02\\t\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT00848471\\tValidation of the Quark RMR Calorimeter (Cosmed) Versus Deltatrac II (GE Health Care Clinical Systems)\\tProtocol Quark\\tUNKNOWN\\tHealthy|Obesity\\tDEVICE: Quark RMR|DEVICE: Deltatrac II\\tHospices Civils de Lyon\\tCentre de Recherche en Nutrition Humaine Rhone-Alpe\\t30.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH\\t2009-01\\t2009-12\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT06135571\\tStudy on the No.253 Lymph Node Metastasis Patterns in Left-Sided Colon and Rectal Cancer\\t\\tRECRUITING\\tColorectal Cancer|Lymph Node Metastasis\\tPROCEDURE: Laparoscopic colorectal surgery\\tCancer Institute and Hospital\",\" Chinese Academy of Medical Sciences\\tPeking Union Medical College Hospital|Peking University Cancer Hospital & Institute|China-Japan Friendship Hospital|Chinese PLA General Hospital\\t3000.0\\tOTHER\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2023-09-01\\t2026-09-01\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT01189071\\tPreoperative Use of Darifenacin (Enablex) to Alleviate Postoperative Ureteral Stent Pain\\t\\tTERMINATED\\tOveractive Bladder|Renal Colic|Pain\",\" Postoperative\\tDRUG: Darifenacin\\tUniversity of Missouri-Columbia\\t\\t3.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT\\t2009-08\\t2011-07\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT00728871\\tThe Correlations Between HPV L1-Specific Immunologic Responses in Cervical Cancer and Cervical Intraepithelial Neoplasia (CIN) Patients and Their Prognosis\\t\\tUNKNOWN\\tCervical Cancer|Cervical Intraepithelial Neoplasia\\tPROCEDURE: peripheral blood isolation\\tNational Taiwan University Hospital\\t\\t600.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE\\t2005-12\\t2011-12\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT05592171\\tOcclusafe® Assisted MW Alone or With DEB-TACE Compared to MW With DEB-TACE in the Treatment of HCC\\tSEASON-HCC\\tRECRUITING\\tHCC\\tPROCEDURE: Microwave ablation + Occlusafe + DEB-TACE|PROCEDURE: Microwave ablation + Occlusafe|PROCEDURE: Microwave ablation + DEB-TACE\\tUniversity of Pisa\\tAzienda Ospedaliera Città della Salute e della Scienza di Torino|Fondazione Policlinico Universitario Agostino Gemelli IRCCS|Azienda Ospedaliera Universitaria Policlinico|IRCCS Azienda Ospedaliero-Universitaria di Bologna|Terumo Europe N.V.|Azienda Ospedaliero\",\" Universitaria Pisana\\t60.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT\\t2022-10-17\\t2025-10-17\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT00520871\\tThe Water-Blueberry Study\\t\\tCOMPLETED\\tCardiovascular Disease\\tDRUG: Blueberry juice\\tUniversity of Oslo\\tUllevaal University Hospital\\t62.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE|Primary Purpose: PREVENTION\\t2003-03\\t2004-04\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT05913271\\tStudy on the Correlation Between NAT2(N-acetyltransferase2) Gene Polymorphism and CrCl(Creatine Clreance) and the Efficacy and Safety of Levosimendan in Patients With Severe Heart Failure\\t\\tRECRUITING\\tHeart Failure|Levosimendan|Efficacy|Safety\\t\\tYi Han\\tQianfoshan Hospital\\t352.0\\tOTHER\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2023-05-30\\t2025-05-30\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04006171\\tComparison of Serum C Type Natriuretic Peptide Levels Between Polycystic Ovary Syndrome Patients and Healthy Women\\tCNP\\tCOMPLETED\\tPolycystic Ovary Syndrome|c Type Natriuretic Peptide|Menstrual Irregularity|Hyperandrogenism\\tDIAGNOSTIC_TEST: C type natriuretic peptide\\tNear East University\",\" Turkey\\t\\t90.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC\\t2019-07-15\\t2020-09-01\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04370171\\tManagement of Diabetic Patients With Telemedicine in the Context of the Covid-19 Epidemic\\tTeleCoviDiab\\tCOMPLETED\\tDiabetes|Covid-19\\tOTHER: care modalities|OTHER: Teleconsultation either by phone or by computer consultation\\tUniversity Hospital\", Strasbourg,\" France\\t\\t610.0\\tOTHER\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2020-05-04\\t2020-05-29\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04340271\\tThe Clinical Utility of Extracorporeal Shock Wave Therapy on Burns\\t\\tCOMPLETED\\tBurn Scar\\tOTHER: Extracorporeal shock wave therapy|OTHER: conventional occupational therapy\\tHangang Sacred Heart Hospital\\t\\t48.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Interv\n\n*** WARNING: max output size exceeded, skipping output. ***\n\n,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT05974371\\tEpisodic Memory Integration and Interference\\t\\tNOT_YET_RECRUITING\\tEpisodic Memory\\tOTHER: emotional context similarity\\tBoston College\\t\\t150.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE\\t2024-08\\t2027-08\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT03713671\\tGait and Balance Parameters Before and After Parathyroidectomy in Patients With Primary Hyperparathyroidism\\t\\tCOMPLETED\\tPrimary Hyperparathyroidism\\tDIAGNOSTIC_TEST: gait analysis\\tRecep Tayyip Erdogan University Training and Research Hospital\\tHacettepe University|Ankara Education and Research Hospital\\t40.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SCREENING\\t2021-10-17\\t2023-08-27\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02645071\\tBrief Program in Reducing Sedentary Behavior and Promoting Physical Exercise\\t\\tCOMPLETED\\tPhysical Activity\\tBEHAVIORAL: Physical Activity\\tThe University of Hong Kong\\tHong Kong Jockey Club Charities Trust\\t141.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION\\t2015-07\\t2017-07\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04004871\\tInduction Chemotherapy With Nab-paclitaxel\",\" Cisplatin and Fluorouracil for Locoregionally Advanced Nasopharyngeal Carcinoma\\t\\tUNKNOWN\\tNasopharyngeal Carcinoma|Nasopharyngeal Cancer|Nasopharynx Cancer\\tDRUG: Nab-paclitaxel\",\" Cisplatin and Fluorouracil|RADIATION: concurrent chemoradiotherapy\\tGuangxi Medical University\\tSecond Affiliated Hospital of Guangxi Medical University|Guilin Medical University\",\" China|Liuzhou Workers Hospital|Wuzhou Red Cross Hospital\\t60.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT\\t2019-07-05\\t2022-06-30\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT05953571\\tLaparoscopic Assisted Dismembered Pyeloplasty Versus Open Pyeloplasty in (UPJO) With Poorly Function Kidney in Pediatrics\\t\\tCOMPLETED\\tUretro-pelvic Junction Obstruction|Poorly Function Kidney\\tPROCEDURE: Dismembered Pyeloplasty\\tAl-Azhar University\\tUniversity Hospital Fattouma Bourguiba\\t65.0\\tOTHER\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2022-01-08\\t2023-06-30\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02570971\\tMannitol Versus Supportive Care in Ciguatera Fish Poisoning\\t\\tUNKNOWN\\tCiguatoxin\\tDRUG: Mannitol\\tUniversity of South Florida\\tFlorida Poison Control Center\\t200.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: TREATMENT\\t2015-10\\t\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT03987971\\tAcupuncture on GB26 to Treat Chronic Low Back Pain\\t\\tUNKNOWN\\tChronic Low-back Pain\\tOTHER: acupuncture\\tWenzhou Medical University\\tQingtian People\\'s hospital\\t114.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT\\t2020-01\\t2021-07\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT01425671\\tNeural Oscillations as Genetic and Functional Biomarkers in Normal and Disease States\\t\\tACTIVE_NOT_RECRUITING\\tSchizophrenia|Schizoaffective Disorder|Schizophreniform Disorder\\t\\tUniversity of Maryland\",\" Baltimore\\tNational Institute of Mental Health (NIMH)\\t800.0\\tOTHER\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2010-11-30\\t2024-06\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04962971\\tComparative Effect of 3 Different Cranberry Extracts on Cystitis Related Urinary Comfort in Women\\t\\tCOMPLETED\\tRecurrent Cystitis\\tDIETARY_SUPPLEMENT: X|DIETARY_SUPPLEMENT: Y|DIETARY_SUPPLEMENT: Z\\tCEN Biotech\\tNexira|CEN Nutriment\\t216.0\\tINDUSTRY\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2020-09-01\\t2022-02-01\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02827071\\tOcular Imaging Study Using Advanced OCT\\t\\tUNKNOWN\\tRetinal Vascular Disorder|Macular Degeneration\\t\\tUniversity of California\",\" Los Angeles\\t\\t1000.0\\tOTHER\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2016-07\\t\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04236271\\tTELEsurveillance of Patients in PostopErative Bridge surgeryAge CoronairE\\tTELE-PEACE\\tCOMPLETED\\tCoronary Artery Bypass\\tDEVICE: connected objects\\tAssistance Publique - Hôpitaux de Paris\\tGFI\\t33.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER\\t2020-03-13\\t2022-12-31\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT01780571\\tCPAP/PSV Preoxygenation in Obese Patients\\t\\tCOMPLETED\\tObesity|Anaesthesia\\tPROCEDURE: CPAP 5 cm H2O + PSV 5 cm H2O\\tKarolinska Institutet\\t\\t44.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION\\t2009-05\\t2012-12\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT05078671\\tPharmacokinetic Boosting of Olaparib to Improve Exposure\",\" Tolerance and Cost-effectiveness\\tPROACTIVE\\tRECRUITING\\tCancer\\tDRUG: Olaparib|DRUG: Cobicistat\\tRadboud University Medical Center\\t\\t160.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT\\t2021-12-15\\t2025-12-31\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02529371\\tPre-Marketing Feasibility Evaluation of the UriCap-RM - Urine Collection in Hospitalized Male Patients\\t\\tUNKNOWN\\tUrinary Incontinence\\tDEVICE: UriCap-RM\\tG.R. Dome Medical Ltd.\\t\\t30.0\\tINDUSTRY\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE\\t2015-09\\t2015-10\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02309671\\tA Dose-response Trial Using FE 999049 in Japanese Women Undergoing in Vitro Fertilisation (IVF) / Intracytoplasmic Sperm Injection (ICSI) Treatment\\t\\tCOMPLETED\\tInfertility\\tDRUG: FE 999049|DRUG: follitropin beta\\tFerring Pharmaceuticals\\t\\t159.0\\tINDUSTRY\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT\\t2014-12\\t2016-09\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT03876171\\tCulturally Modified Family Based Therapy for Haitian Youth in South Florida\\t\\tCOMPLETED\\tProblem Behavior\\tBEHAVIORAL: Haitian youth and family intervention study: family functioning|BEHAVIORAL: Haitian youth intervention study: youth psychoeducational|BEHAVIORAL: Haitian family intervention study: family psychoeducational|BEHAVIORAL: Diversion Programs\\tUniversity of Miami\\tNational Institute on Drug Abuse (NIDA)\\t44.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT\\t2019-04-01\\t2022-12-31\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT05031871\\tPharmacokinetics of HR17031 Injection in Healthy Subjects\\t\\tCOMPLETED\\tType 2 Diabetes Mellitus\\tDRUG: HR17031 injection ；INS068 injection；SHR20004 injection|DRUG: HR17031 injection ；INS068 injection；SHR20004 injection|DRUG: HR17031 injection ；INS068 injection；SHR20004 injection|DRUG: HR17031 injection ；INS068 injection；SHR20004 injection\\tJiangsu HengRui Medicine Co.\",\" Ltd.\\t\\t24.0\\tINDUSTRY\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT\\t2021-09-02\\t2021-11-19\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04769271\\tIntra-pocket Application of Tea Tree Oil Gel in the Treatment of Stage-2 Periodontitis\\t\\tCOMPLETED\\tPeriodontitis\\tPROCEDURE: Scaling and Root Planing|DRUG: Scaling and Root Planing with tea tree oil\\tAlexandria University\\t\\t30.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT\\t2019-11-10\\t2020-08-25\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT06044571\\tOptimizing Telehealth-delivery of a Weight Loss Intervention in Older Adults\\t\\tNOT_YET_RECRUITING\\tObesity|Multiple Chronic Conditions\\tOTHER: Prescriptive|BEHAVIORAL: Behavioral\\tUniversity of North Carolina\",\" Chapel Hill\\tNational Institute on Aging (NIA)\\t180.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (PARTICIPANT\",\" CARE_PROVIDER)|Primary Purpose: TREATMENT\\t2024-03-01\\t2027-09-01\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT01889771\\tA Cost-effectiveness Study of Nicotine Patches Distributed Through a Quitline\\t\\tCOMPLETED\\tSmoking Cessation\\tDRUG: Nicotine Patch\\tUniversity of Colorado\",\" Denver\\t\\t1495.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH\\t2010-03\\t2012-03\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT03077971\\tEffectiveness of Acceptance and Commitment Therapy Self-Help for Carers of People With Multiple Sclerosis\\t\\tUNKNOWN\\tCarer Stress Syndrome\\tBEHAVIORAL: ACT Self-Help|BEHAVIORAL: ACT Self-Help with Telephone Support\\tUniversity of Nottingham\\t\\t24.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE\\t2016-12-01\\t2018-06\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02912871\\tSubthalamotomy by ExAblate Transcranial System to Treat Motor Features of Parkinson\\'s Disease\\t\\tCOMPLETED\\tParkinson\\'s Disease\\tOTHER: MRIgHIFU unilateral subthalamotomy\\tFundación de investigación HM\\tInsightech\\t10.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT\\t2016-04\\t2017-01\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT03548571\\tDendritic Cell Immunotherapy Against Cancer Stem Cells in Glioblastoma Patients Receiving Standard Therapy\\tDEN-STEM\\tACTIVE_NOT_RECRUITING\\tGlioblastoma\\tBIOLOGICAL: Dendritic cell immunization|DRUG: Adjuvant temozolomide\\tOslo University Hospital\\t\\t60.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT\\t2018-04-26\\t2025-05-01\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT01449071\\tStudy Evaluating the Pharmacokinetics and Safety of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE)\\t\\tCOMPLETED\\tSystemic Lupus Erythematosus\\tBIOLOGICAL: Placebo|BIOLOGICAL: Epratuzumab 400 mg|BIOLOGICAL: Epratuzumab 1200 mg|BIOLOGICAL: Epratuzumab 100 mg|BIOLOGICAL: Epratuzumab 600 mg\\tUCB Pharma\\t\\t20.0\\tINDUSTRY\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT\\t2011-10\\t2013-03\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT03530371\\tIntranasal Dexmedetomidine for Sedated Hearing Testing\\t\\tCOMPLETED\\tAuditory Brainstem Response\\tDRUG: Dexmedetomidine Hydrochloride\\tFondation Lenval\\t\\t60.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC\\t2019-05-02\\t2021-12-31\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT05921071\\tDo Patients Who Received Tranexamic Acid in Vaginal Hysterectomy Loose Les Blood\",\" Comparing to Patients Who Did Not?\\t\\tRECRUITING\\tVaginal Hysterectomy\\tDRUG: Tranexamic acid|DRUG: Placebo\\tWolfson Medical Center\\t\\t150.0\\tOTHER_GOV\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE\\t2023-01-22\\t2025-01-01\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04974671\\tTrial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma\\t\\tRECRUITING\\tRenal Cell Carcinoma|Metastatic Renal Cell Carcinoma|Oligoprogressive|Progression\\tRADIATION: Stereotactic Body Radiation Therapy\\tYale University\\t\\t30.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT\\t2022-08-08\\t2027-04-01\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT00080171\\tOsteoarthritis Initiative (OAI): A Knee Health Study\\t\\tCOMPLETED\\tOsteoarthritis|Knee Osteoarthritis\\t\\tNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)\\tGlaxoSmithKline|Merck Sharp & Dohme LLC|Novartis|Pfizer\\t4796.0\\tNIH\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2004-02\\t2015-10\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT00368771\\tA Six-month Study to Compare Outcome Differences and Visceral Response ... Irritable Bowel Syndrome\\t\\tCOMPLETED\\tIrritable Bowel Syndrome\\tBEHAVIORAL: IBS Stress Management|BEHAVIORAL: IBS Symptom Management|BEHAVIORAL: IBS Educational Training\\tUniversity of California\",\" Los Angeles\\tNational Institute of Nursing Research (NINR)\\t163.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT\\t2002-07\\t2010-05\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04979871\\tSARS-CoV-2 Antibodies and Virus Neutralisation in a Cohort Vaccinted Against COVID-19\\tDER-CoV2-001\\tCOMPLETED\\tVaccine Reaction\\tPROCEDURE: Venous bleeding\\tUniversity of Zurich\\t\\t50.0\\tOTHER\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2021-07-22\\t2021-12-31\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04097171\\tThe Effect of Diet Composition on Performance\", Expenditure, Blood Lipids,\" and Appetite Hormones in Highly Trained Cyclists\\tDCAP\\tCOMPLETED\\tEndurance Cycling Performance\\tOTHER: Diet\\tTexas Christian University\\t\\t34.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE\\t2019-11-11\\t2020-03-30\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT06199271\\tNeoadjuvant Adebrelimab Plus Dalpiciclib in Head and Neck Squamous Cell Carcinoma\\t\\tNOT_YET_RECRUITING\\tHead and Neck Squamous Cell Carcinoma\\tDRUG: Adebrelimab and dalpiciclib\\tZhongzheng Xiang\\t\\t30.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT\\t2024-01-31\\t2026-12-31\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04032171\\tStudy of Evobrutinib in Participants With RMS\\t\\tTERMINATED\\tRelapsing-remitting Multiple Sclerosis\\tDRUG: Evobrutinib|DRUG: Avonex®|DRUG: Avonex® matched Placebo|DRUG: Evobrutinib matched Placebo\\tEMD Serono Research & Development Institute\",\" Inc.\\tMerck KGaA\", Darmstadt,\" Germany\\t1.0\\tINDUSTRY\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT\\t2019-09-10\\t2020-05-20\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT05674071\\tApplying an Osteopathic Intervention to Improve Mental Health Symptoms: a Mixed-methods Feasibility Study Protocol.\\t\\tCOMPLETED\\tMental Health Issue\\tBEHAVIORAL: Articulation/HVT|BEHAVIORAL: Soft-tissue massage|BEHAVIORAL: Craniosacral techniques|BEHAVIORAL: Combination of the three interventions: HVT\",\" soft-tissue and craniosacral techniques\\tSwansea University\\tOsteopathic Foundation|University College of Osteopathy\\t32.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT\\t2022-12-20\\t2023-08-01\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT00858871\\tFirst Line Hepato Cellular Carcinoma (HCC)\\tBRISK FL\\tCOMPLETED\\tHepato Cellular Carcinoma (HCC)\\tDRUG: Brivanib|DRUG: Placebo|DRUG: Sorafenib|DRUG: Placebo\\tBristol-Myers Squibb\\t\\t1714.0\\tINDUSTRY\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT\\t2009-05\\t2013-09\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT01776671\\tOnce Daily Gabapentin in the Treatment of Post Amputation Pain\\t\\tUNKNOWN\\tPain|Quality of Life\\tDRUG: Gralise\\tChicago Anesthesia Pain Specialists\\t\\t16.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT\\t2013-02\\t2018-12\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT01363271\\tCost Study of Linezolid Versus Vancomycin Among Previously Hospitalized Patients\\t\\tCOMPLETED\\tComplicated Skin and Structure Infection|Nosocomial Pneumonia\\tDRUG: Linezolid|DRUG: Vancomycin|DRUG: Linezolid|DRUG: Vancomycin\\tPfizer\\tUniversity of Maryland|Lodise & Lodise\",\" LLC\\t7260.0\\tINDUSTRY\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2011-05\\t2012-05\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT01282671\\tEffects of Deep Breathing Exercises Two Months After Cardiac Surgery\\t\\tCOMPLETED\\tCABG|Valve Surgery\\tOTHER: Breathing exercises\\tUppsala University\\tThe Swedish Research Council|Örebro County Council\\t357.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT\\t2007-09\\t2012-08\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT05683171\\tA Phase 1/2\",\" Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma\\t\\tRECRUITING\\tLymphoma\\tDRUG: Rituximab|DRUG: Lenalidomide|DRUG: Valemetostat\\tM.D. Anderson Cancer Center\\tDaiichi Sankyo\\t60.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT\\t2023-05-19\\t2027-09-30\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT05334771\\tEarly Detection of Endolymphatic Hydrops in Hypothyroid Patients\\t\\tNOT_YET_RECRUITING\\tHypothyroidism\\tDEVICE: Dual band pure tune audiometer\\tAssiut University\\t\\t50.0\\tOTHER\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2022-09\\t2025-04\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04718571\\tAn Ecological Analysis of Nontuberculous Mycobacteria in the Geneva Area (2015-2020)\\t\\tCOMPLETED\\tEcology of Nontubercuous Mycobacteria|Geneva Area\\t\\tUniversity Hospital\",\" Geneva\\t\\t231.0\\tOTHER\\tOBSERVATI'"
     ]
    }
   ],
   "source": [
    "dbutils.fs.head(\"FileStore/tables/clinicaltrial_2023.csv\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "040072de-fcf3-4212-babe-04ba8ec2613c",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [],
   "source": [
    "janirdd = sc.textFile('/FileStore/tables/clinicaltrial_2023.csv')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "3bf6ce69-8be5-4d43-bbd3-e572cd54f8b3",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [],
   "source": [
    "from pyspark.sql import Row\n",
    "cleanedRDD = janirdd.filter(lambda line: line.strip() != '')\n",
    "fieldsRDD = cleanedRDD.map(lambda line: line.split('\\t'))\n",
    "cleanRDD = fieldsRDD.map(lambda row: [field.rstrip(',') for field in row])\n",
    "cleanRDD = cleanRDD.map(lambda fields: [field.replace('\"', '') for field in fields])\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "099680f0-fa6f-4682-94dd-24625121b19e",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['Id', 'Study Title', 'Acronym', 'Status', 'Conditions', 'Interventions', 'Sponsor', 'Collaborators', 'Enrollment', 'Funder Type', 'Type', 'Study Design', 'Start', 'Completion']\n['NCT03630471', 'Effectiveness of a Problem-solving Intervention for Common Adolescent Mental Health Problems in India', 'PRIDE', 'COMPLETED', 'Mental Health Issue (E.G., Depression, Psychosis, Personality Disorder, Substance Abuse)', \"BEHAVIORAL: PRIDE 'Step 1' problem-solving intervention|BEHAVIORAL: Enhanced usual care\", 'Sangath', 'Harvard Medical School (HMS and HSDM)|London School of Hygiene and Tropical Medicine', '250.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT', '2018-08-20', '2019-02-28']\n['NCT05992571', 'Oral Ketone Monoester Supplementation and Resting-state Brain Connectivity', '', 'RECRUITING', 'Cerebrovascular Function|Cognition', 'OTHER: Placebo|DIETARY_SUPPLEMENT: β-OHB', 'McMaster University', \"Alzheimer's Society of Brant, Haldimand Norfolk, Hamilton Halton\", '30.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE', '2023-10-25', '2024-08']\n['NCT00237471', 'Impact of Tight Glycaemic Control in Acute Myocardial Infarction', '', 'TERMINATED', 'Myocardial Infarct|Hyperglycemia', 'DRUG: Insulin (tight blood glucose control)', 'Melbourne Health', 'National Health and Medical Research Council, Australia|Bristol-Myers Squibb', '40.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT', '2005-10', '2006-05']\n['NCT03820271', 'New Prognostic Predictive Models of Mortality of Decompensated Cirrhotic Patients Waiting for Liver Transplantation', 'SUPERMELD', 'RECRUITING', 'Decompensated Cirrhosis|Liver Transplantation', 'OTHER: SuperMELD', 'Assistance Publique - Hôpitaux de Paris', '', '500.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER', '2020-10-01', '2023-10-01']\n['NCT06229171', 'InTake Care: Development and Validation of an Innovative, Personalized Digital Health Solution for Medication Adherence Support in Cardiovascular Prevention', 'InTakeCare', 'NOT_YET_RECRUITING', 'Hypertension|Treatment Adherence and Compliance|Digital Health', 'OTHER: adherence support system based on a vocal assistant', 'Istituto Auxologico Italiano', 'Istituti Clinici Scientifici Maugeri SpA|Politecnico di Milano', '206.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER', '2024-10-01', '2026-04-01']\n['NCT02945371', 'Tailored Inhibitory Control Training to Reverse EA-linked Deficits in Mid-life', 'REV', 'COMPLETED', 'Smoking|Alcohol Drinking|Prescription Drug Abuse|Substance-Related Disorders|Oral Intake Reduced', 'BEHAVIORAL: Person-centered inhibitory control training|BEHAVIORAL: Active behavioral response training', 'University of Oregon', '', '103.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION', '2014-09', '2016-05']\n['NCT01055171', 'Neuromodulation of Trauma Memories in PTSD & Alcohol Dependence', '', 'COMPLETED', 'Alcohol Dependence|PTSD', 'DRUG: Propranolol|DRUG: Placebo', 'Medical University of South Carolina', 'National Institute on Alcohol Abuse and Alcoholism (NIAAA)', '44.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT', '2010-01', '2012-08']\n['NCT01125371', 'Computerized Brief Alcohol Intervention (BI) for Binge Drinking HIV At-Risk and Infected Women', '', 'COMPLETED', 'Alcohol; Harmful Use|Binge Drinking|Risk Behavior|HIV Infection', 'BEHAVIORAL: Computerized brief alcohol intervention + IVR booster calls|BEHAVIORAL: Computerized brief alcohol intervention|BEHAVIORAL: Attention Control', 'Johns Hopkins University', 'National Institute on Alcohol Abuse and Alcoholism (NIAAA)', '439.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT', '2011-10', '2016-06-07']\n['NCT02554071', 'Manitoba Pharmacist Initiated Smoking Cessation Pilot Project', '', 'COMPLETED', 'Smoking Cessation', 'OTHER: Pharmacist - Smoking Cessation Support', 'University of Manitoba', 'Govenment of Manitoba|Canadian Foundation for Pharmacy|Neighbourhood Pharmacy Association of Canada', '119.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE', '2014-01', '2014-11']\n['NCT01772771', 'Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program', '', 'RECRUITING', 'Glioma|Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm|Melanoma|Sarcoma', 'PROCEDURE: Biospecimen Collection|OTHER: Genetic Testing|OTHER: Medical Chart Review', 'M.D. Anderson Cancer Center', 'National Cancer Institute (NCI)', '12000.0', 'OTHER', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2012-03-01', '2033-03-01']\n['NCT02633371', 'A Pilot Study Exploring the Efficacy and Safety of Topical Oxybutynin 3% Gel for Primary Focal Hyperhidrosis in Adolescents and Young Adults', '', 'COMPLETED', 'Hyperhidrosis', 'DRUG: Oxybutynin 3% gel', 'University of Colorado, Denver', 'Society for Pediatric Dermatology', '10.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT', '2016-02', '2017-05']\n['NCT03400371', 'Biology of Juvenile Myoclonic Epilepsy', 'BIOJUME', 'RECRUITING', 'Juvenile Myoclonic Epilepsy', 'OTHER: Blood draw|OTHER: Existing samples', \"King's College London\", \"King's College Hospital NHS Trust|Charles University, Czech Republic|Hopital Universitaire Robert-Debre|Vestre Viken Hospital Trust|The Hospital for Sick Children|Cardiff University|Odense University Hospital\", '1000.0', 'OTHER', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2017-07-13', '2026-06-30']\n['NCT00120471', 'Safety and Blood Levels of Tenofovir Disoproxil Fumarate in HIV Infected Pregnant Women and Their Babies', '', 'COMPLETED', 'HIV Infections', 'DRUG: Tenofovir disoproxil fumarate|DRUG: Tenofovir disoproxil fumarate|DRUG: Tenofovir disoproxil fumarate', 'National Institute of Allergy and Infectious Diseases (NIAID)', 'Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute on Drug Abuse (NIDA)|National Institute of Mental Health (NIMH)', '122.0', 'NIH', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION', '2006-11', '2011-12']\n['NCT04784871', 'Promoting Wellbeing: The Five Ways to All Intervention', '5WaysA', 'COMPLETED', 'Wellbeing|Health Attitude|Quality of Life', 'BEHAVIORAL: 5waysA Intervention|BEHAVIORAL: 5waysA Active wait-list control|BEHAVIORAL: 5waysA Inactive wait-list control', 'University of Oslo', 'Norwegian Institute of Public Health|Norwegian Council for Mental Health|The Dam Foundation', '970.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION', '2021-03-04', '2023-02-24']\n['NCT02383771', 'Reversal of the Anti-platelet Effects of Ticagrelor', 'REVERSAL', 'COMPLETED', 'Coronary Artery Disease', 'DRUG: Ticagrelor|DRUG: Aspirin + Ticagrelor|DRUG: Control|DRUG: Aspirin + Ticagrelor', 'The First Affiliated Hospital with Nanjing Medical University', 'National Natural Science Foundation of China', '64.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT', '2015-03', '2016-12']\n['NCT03269071', 'Neural Stem Cell Transplantation in Multiple Sclerosis Patients', 'STEMS', 'COMPLETED', 'Progressive Multiple Sclerosis', 'DRUG: human fetal-derived Neural Stem Cells (hNSCs)', 'IRCCS San Raffaele', 'Fondazione Italiana Sclerosi Multipla', '4.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT', '2017-05-17', '2021-07-31']\n['NCT01659671', 'RCT of the Effect of Uvulopalatopharyngoplasty Compared to Expectancy in Patients With Obstructive Sleep Apnea', 'SKUP3', 'COMPLETED', 'Obstructive Sleep Apnea Syndrome', 'PROCEDURE: Uvulopalatopharyngoplasty', 'Karolinska University Hospital', 'Karolinska Institutet', '65.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT', '2007-06', '2014-05']\n['NCT04765371', 'Comparison Between Prednisolone and Dexamethasone on Mortality in Patients on Oxygen Therapy, With CoViD-19', 'COPreDex', 'COMPLETED', 'Coronavirus Infection', 'DRUG: DEXAMETHASONE|DRUG: PREDNISOLONE', 'Hôpital NOVO', '', '89.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT', '2021-03-03', '2022-05-13']\n['NCT02830971', 'Developing a Standardized Learning Curve', '', 'COMPLETED', 'Registered Nurses|Nursing Personnel|Motor Skills', 'PROCEDURE: Doing Different ICU techniques and skills', 'Baqiyatallah Medical Sciences University', 'Shahid Beheshti University|Tehran University of Medical Sciences', '60.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE', '2016-07', '2021-04-12']\n['NCT00416871', 'Interleukin-2 and Interferon in Treating Patients With Metastatic Kidney Cancer', '', 'COMPLETED', 'Kidney Cancer', 'BIOLOGICAL: aldesleukin|BIOLOGICAL: recombinant interferon alfa', 'Centre Leon Berard', '', '220.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: |Masking: NONE|Primary Purpose: TREATMENT', '', '2006-02']\n['NCT05900271', 'Dutch-Depression Outcome Trial Comparing 5 Day Multi Daily Neuronavigated Theta Burst Sessions With 6 Weeks rTMS', 'DDOT', 'ACTIVE_NOT_RECRUITING', 'Treatment Resistant Depression', 'DEVICE: rTMS|DEVICE: iTBS', 'Amsterdam UMC, location VUmc', 'Radboud University Medical Center|University Medical Center Groningen|Maastricht University|Trimbos|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)', '108.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT', '2023-11-15', '2027-12']\n['NCT02469571', 'Modulation of Gut Microbiota in Early Sepsis: A Pilot Study', 'MGM-sepsis', 'COMPLETED', 'Sepsis', 'DIETARY_SUPPLEMENT: Winclove 607|DIETARY_SUPPLEMENT: Placebo', 'Medical University of Graz', '', '15.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION', '2015-09-01', '2018-03-01']\n['NCT05807971', 'Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ATH-063 in Healthy Subjects', '', 'RECRUITING', 'Inflammatory Bowel Diseases|Crohn Disease|Ulcerative Colitis|Autoimmune Diseases', 'DRUG: ATH-063|DRUG: Placebo', 'Athos Therapeutics Inc', 'Syneos Health|Athos Therapeutics Australia Pty Ltd', '76.0', 'INDUSTRY', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT', '2023-04-06', '2024-02-08']\n['NCT02083471', \"Cow's Milk and Hen's Egg Hyposensitization in Adults\", '', 'UNKNOWN', \"Egg Allergy|Cow's Milk Allergy\", \"DIETARY_SUPPLEMENT: Specific Oral Tolerance Induction with Egg or Cow's milk\", 'Turku University Hospital', '', '40.0', 'OTHER_GOV', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT', '2015-04', '2017-05']\n['NCT01062971', 'Clinical Study of A Fixed Combination of Timolol-Brimonidine-Dorzolamide', '', 'COMPLETED', 'Primary Open Angle Glaucoma|Ocular Hypertension', 'DRUG: dorzolamide-timolol-brimonidine', 'Laboratorios Sophia S.A de C.V.', '', '124.0', 'INDUSTRY', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT', '2006-02', '2008-06']\n['NCT03928171', 'The Effect of Intra-abdominal Pressure on Peritoneal Perfusion During Laparoscopic Colorectal Surgery', 'PERFUSION', 'COMPLETED', 'Laparoscopic Surgery|Pneumoperitoneum', 'OTHER: Intra-abdominal pressure during laparoscopy', 'Radboud University Medical Center', '', '30.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT', '2018-06-13', '2018-12-24']\n['NCT00897871', 'Evaluating the Side Effects and How Well Anticancer Drugs Work in Very Young Patients With Cancer', '', 'UNKNOWN', 'Unspecified Childhood Solid Tumor, Protocol Specific', 'DRUG: carboplatin|DRUG: cyclophosphamide|DRUG: etoposide phosphate|GENETIC: gene expression analysis|GENETIC: polymorphism analysis|OTHER: pharmacological study', \"Children's Cancer and Leukaemia Group\", '', '60.0', 'OTHER', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2007-02', '']\n['NCT00848471', 'Validation of the Quark RMR Calorimeter (Cosmed) Versus Deltatrac II (GE Health Care Clinical Systems)', 'Protocol Quark', 'UNKNOWN', 'Healthy|Obesity', 'DEVICE: Quark RMR|DEVICE: Deltatrac II', 'Hospices Civils de Lyon', 'Centre de Recherche en Nutrition Humaine Rhone-Alpe', '30.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH', '2009-01', '2009-12']\n['NCT06135571', 'Study on the No.253 Lymph Node Metastasis Patterns in Left-Sided Colon and Rectal Cancer', '', 'RECRUITING', 'Colorectal Cancer|Lymph Node Metastasis', 'PROCEDURE: Laparoscopic colorectal surgery', 'Cancer Institute and Hospital, Chinese Academy of Medical Sciences', 'Peking Union Medical College Hospital|Peking University Cancer Hospital & Institute|China-Japan Friendship Hospital|Chinese PLA General Hospital', '3000.0', 'OTHER', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2023-09-01', '2026-09-01']\n['NCT01189071', 'Preoperative Use of Darifenacin (Enablex) to Alleviate Postoperative Ureteral Stent Pain', '', 'TERMINATED', 'Overactive Bladder|Renal Colic|Pain, Postoperative', 'DRUG: Darifenacin', 'University of Missouri-Columbia', '', '3.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT', '2009-08', '2011-07']\n['NCT00728871', 'The Correlations Between HPV L1-Specific Immunologic Responses in Cervical Cancer and Cervical Intraepithelial Neoplasia (CIN) Patients and Their Prognosis', '', 'UNKNOWN', 'Cervical Cancer|Cervical Intraepithelial Neoplasia', 'PROCEDURE: peripheral blood isolation', 'National Taiwan University Hospital', '', '600.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE', '2005-12', '2011-12']\n['NCT05592171', 'Occlusafe® Assisted MW Alone or With DEB-TACE Compared to MW With DEB-TACE in the Treatment of HCC', 'SEASON-HCC', 'RECRUITING', 'HCC', 'PROCEDURE: Microwave ablation + Occlusafe + DEB-TACE|PROCEDURE: Microwave ablation + Occlusafe|PROCEDURE: Microwave ablation + DEB-TACE', 'University of Pisa', 'Azienda Ospedaliera Città della Salute e della Scienza di Torino|Fondazione Policlinico Universitario Agostino Gemelli IRCCS|Azienda Ospedaliera Universitaria Policlinico|IRCCS Azienda Ospedaliero-Universitaria di Bologna|Terumo Europe N.V.|Azienda Ospedaliero, Universitaria Pisana', '60.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT', '2022-10-17', '2025-10-17']\n['NCT00520871', 'The Water-Blueberry Study', '', 'COMPLETED', 'Cardiovascular Disease', 'DRUG: Blueberry juice', 'University of Oslo', 'Ullevaal University Hospital', '62.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE|Primary Purpose: PREVENTION', '2003-03', '2004-04']\n['NCT05913271', 'Study on the Correlation Between NAT2(N-acetyltransferase2) Gene Polymorphism and CrCl(Creatine Clreance) and the Efficacy and Safety of Levosimendan in Patients With Severe Heart Failure', '', 'RECRUITING', 'Heart Failure|Levosimendan|Efficacy|Safety', '', 'Yi Han', 'Qianfoshan Hospital', '352.0', 'OTHER', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2023-05-30', '2025-05-30']\n['NCT04006171', 'Comparison of Serum C Type Natriuretic Peptide Levels Between Polycystic Ovary Syndrome Patients and Healthy Women', 'CNP', 'COMPLETED', 'Polycystic Ovary Syndrome|c Type Natriuretic Peptide|Menstrual Irregularity|Hyperandrogenism', 'DIAGNOSTIC_TEST: C type natriuretic peptide', 'Near East University, Turkey', '', '90.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC', '2019-07-15', '2020-09-01']\n['NCT04370171', 'Management of Diabetic Patients With Telemedicine in the Context of the Covid-19 Epidemic', 'TeleCoviDiab', 'COMPLETED', 'Diabetes|Covid-19', 'OTHER: care modalities|OTHER: Teleconsultation either by phone or by computer consultation', 'University Hospital, Strasbourg, France', '', '610.0', 'OTHER', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2020-05-04', '2020-05-29']\n['NCT04340271', 'The Clinical Utility of Extracorporeal Shock Wave Therapy on Burns', '', 'COMPLETED', 'Burn Scar', 'OTHER: Extracorporeal shock wave therapy|OTHER: conventional occupational therapy', 'Hangang Sacred Heart Hospital', '', '48.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT', '2020-04-15', '2020-05-31']\n['NCT03075371', 'Homeostatic and Non-homeostatic Processing of Food Cues in Anorexia Nervosa', '', 'COMPLETED', 'Anorexia Nervosa|Healthy', 'OTHER: Glucose|OTHER: Placebo', 'University of Heidelberg Medical Center', 'German Research Foundation', '85.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: BASIC_SCIENCE', '2014-09', '2019-02']\n['NCT05966571', 'Ovarian Innervation Study in Patients With Polycystic Ovary Syndrome (PCOS)', '', 'RECRUITING', 'Polycystic Ovary Syndrome', 'PROCEDURE: Ovary Biopsie', 'Albanian University', '', '50.0', 'OTHER', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2023-07-01', '2024-12-01']\n['NCT03313271', 'China Lymphoma Patient Registry Study', 'CLAP', 'RECRUITING', 'Lymphoma', '', 'Jun Zhu', 'Peking University First Hospital|Tianjin Medical University Cancer Hospital|Zhejiang Cancer Hospital|Heilongjiang Cancer Hospital|Sipai(Beijing)Network Technology Co Ltd', '5000.0', 'OTHER', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2017-05-17', '2027-08-30']\n['NCT03490071', 'Long-term Follow up of Patients With Longstanding Hip and Groin Pain', 'Lund LHGP', 'RECRUITING', 'Hip Pain Chronic', '', 'Lund University', '', '81.0', 'OTHER', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2018-01-01', '2024-12-31']\n['NCT05801471', 'Clinical Evaluation of Visual Field Change in Glaucoma: an Assessment of Different Models of Progression', '', 'RECRUITING', 'Glaucoma', '', 'Centervue SpA', '', '200.0', 'INDUSTRY', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2022-05-06', '2025-11-06']\n['NCT00266071', 'Study of the Cutaneous Microcirculation in Elderly People', '', 'UNKNOWN', 'Elderly People', 'BEHAVIORAL: Cutaneous response', 'University Hospital, Angers', '', '', 'OTHER_GOV', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2005-12', '']\n['NCT04405271', 'TAF/FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study)', '', 'UNKNOWN', 'Healthcare Workers|COVID-19|SARS-CoV 2', 'DRUG: Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet|DRUG: Placebo', 'Hospital Italiano de Buenos Aires', 'Sociedad Argentina de Infectología (SADI) (Argentine Society of Infectious Diseases)', '1378.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION', '2020-07-31', '2020-11-15']\n['NCT02121171', 'Combined Trab+Trab Versus Combined Trab+Trab With Subconjunctival Implantation of Ologen for Primary Congenital Glaucoma', '', 'UNKNOWN', 'Congenital Glaucoma', 'DEVICE: Ologen Collagen Matrix|PROCEDURE: Combined trabeculotomy-trabeculectomy', 'National Centre of Ophthalmology named after academician Zarifa Aliyeva', 'Aeon Astron Europe B.V.', '40.0', 'OTHER_GOV', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT', '2010-09', '2015-09']\n['NCT01068171', 'Developing a Diabetic Foot Ulcer Protocol', '', 'WITHDRAWN', 'Diabetic Foot Ulcers', 'OTHER: type of footwear|OTHER: collagen dressing with and without silver', 'The University of Texas Health Science Center, Houston', 'Harris County Hospital District|Baylor College of Medicine', '0.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT', '2010-05', '2012-06']\n['NCT04875871', 'Particle-based Partial Tumor Irradiation of Unresectable Bulky Tumors', 'PARTICLE-PATHY', 'RECRUITING', 'Cancer', 'RADIATION: Particle radiotherapy|DIAGNOSTIC_TEST: Magnetic resonance imaging|DIAGNOSTIC_TEST: Computertomography|DIAGNOSTIC_TEST: Copper-64-Diacetyl-bis (N4-methylthiosemicarbazone) Positron Emission Tomography-Computer Tomography (64Cu-ATSM-PET-CT)|DIAGNOSTIC_TEST: 18-F-FluorDesoxyGlukose Positron Emission Tomography-Computer Tomography (18F-FDG-PET-CT)|DIAGNOSTIC_TEST: Blood sampling', 'EBG MedAustron GmbH', 'CW-Research & Management GmbH|Medical University of Vienna|Landesklinkum Wiener Neustadt|Klinik Ottakring', '22.0', 'INDUSTRY', 'INTERVENTIONAL', 'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT', '2021-11-11', '2024-12']\n['NCT00553371', 'Follow-up Evaluation Using CT Scans in Patients Who Have Been Treated For Metastatic Testicular Cancer', '', 'UNKNOWN', 'Testicular Germ Cell Tumor', 'OTHER: biomarker analysis|PROCEDURE: computed tomography', 'Royal Marsden NHS Foundation Trust', '', '300.0', 'OTHER', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2006-04', '']\n['NCT04674371', 'German Point Prevalence Study on CVC', '', 'COMPLETED', 'Data Collection', 'OTHER: central venous catheter insertion', 'Wolfram Schummer, MD, PhD', '', '537.0', 'OTHER', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2022-05-17', '2022-05-20']\n['NCT02321371', 'Effect of Goal Directed Ammonia Lowering Therapy in Acute on Chronic Liver Failure Patients With Hepatic Encephalopathy.', '', 'COMPLETED', 'Acute-On-Chronic Liver Failure', 'DRUG: Lactulose + Rifaximin|DRUG: Lactulose', 'Institute of Liver and Biliary Sciences, India', '', '73.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT', '2014-10-19', '2016-01-31']\n['NCT02344771', 'Perioperative Endothelial Dysfunction', '', 'COMPLETED', 'Myocardial Injury', 'PROCEDURE: Elective colon cancer surgery', 'Zealand University Hospital', '', '31.0', 'OTHER', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2015-03', '2015-06']\n['NCT03354871', 'Developing Models for Fatigue Monitoring in Obstetrics and Gyne- Cology Residents Using Wearables', 'IoT4Resident', 'UNKNOWN', 'Fatigue', '', 'Hillel Yaffe Medical Center', 'International Business Machines (IBM)', '6.0', 'OTHER_GOV', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2017-11', '2018-02-28']\n['NCT02804971', 'Cardiovascular Comorbidities and Bronchiectasis', 'BRONCOCA', 'ACTIVE_NOT_RECRUITING', 'Bronchiectasis', '', 'Centre Hospitalier Intercommunal Creteil', '', '200.0', 'OTHER', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2016-10-25', '2023-12']\n['NCT04591171', 'Assessing the Feasibility of N-of-1 Trials in Children With Hypertension and Chronic Kidney Disease', '', 'COMPLETED', 'Hypertension|Chronic Kidney Diseases', 'PROCEDURE: n-of-1 trial guided clinical decision making', 'The University of Texas Health Science Center, Houston', \"Children's Hospital of Philadelphia|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)\", '9.0', 'OTHER', 'INTERVENTI\n\n*** WARNING: max output size exceeded, skipping output. ***\n\nARALLEL|Masking: NONE|Primary Purpose: TREATMENT', '2022-07-29', '2026-03-20']\n['NCT00300495', 'Study of Amiodarone Given Before Lung Surgery to Prevent Atrial Fibrillation After Lung Resection', '', 'TERMINATED', 'Atrial Fibrillation|Lung Cancer', 'DRUG: Amiodarone|OTHER: Control arm, standard care', 'Beth Israel Deaconess Medical Center', '', '19.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION', '2006-02', '2009-10-13']\n['NCT01240395', 'Mindfulness-based Cognitive Therapy for Individuals With Multiple Chemical Sensitivity', '', 'COMPLETED', 'Multiple Chemical Sensitivity', 'BEHAVIORAL: Mindfulness-based Cognitive Therapy (MBCT)', 'The Danish Research Centre for Chemical Sensitivities', '', '82.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT', '2011-09', '2013-05']\n['NCT03850795', 'HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)', '', 'ACTIVE_NOT_RECRUITING', 'Prostate Cancer Metastatic|Castration-resistant Prostate Cancer', 'DRUG: HC-1119|DRUG: Enzalutamide', 'Hinova Pharmaceuticals USA, Inc.', '', '104.0', 'INDUSTRY', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT', '2021-03-15', '2024-12-31']\n['NCT00748995', 'Neuropsychological and Mental Outcomes of Operation Iraqi Freedom (OIF): A Longitudinal Cohort Study', '', 'ACTIVE_NOT_RECRUITING', 'Stress Disorders, Post-Traumatic', '', 'VA Office of Research and Development', '', '817.0', 'FED', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2010-08-31', '2025-09-30']\n['NCT01549795', 'Liver Transplantation for Hilar Cholangiocarcinoma in Association With Neoadjuvant Radio- and Chemo-therapy', '', 'UNKNOWN', 'Hilar Cholangiocarcinoma|Primary Sclerosing Cholangitis', 'PROCEDURE: Liver transplantation|RADIATION: 45 Gy external radiations|RADIATION: Endoluminal bile duct Brachytherapy|DRUG: Capecitabine|PROCEDURE: Pre liver transplantation laparoscopic hand assisted staging', 'Azienda Ospedaliera di Padova', '', '33.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT', '2012-01', '']\n['NCT00420095', 'A Study for Patients With Diabetes Mellitus (IOPA)', 'IOPA', 'COMPLETED', 'Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2', 'DRUG: Human insulin 30/70|DRUG: Insulin lispro low mix', 'Eli Lilly and Company', '', '117.0', 'INDUSTRY', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT', '2007-01', '2008-01']\n['NCT05023395', 'Safety and Efficacy of MEE-HU Medicus', '(SEM)', 'ACTIVE_NOT_RECRUITING', 'Urinary Tract Infections', 'DRUG: MEE-HU Medicus|OTHER: Placebo', 'Dr. Ahmed Ismail', 'Theodor Bilharz Research Institute|The Cairo Kidney Center|Helwan University|Zagazig University', '200.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT', '2021-10-23', '2024-05-11']\n['NCT03810495', \"The O'Neil Long Acting Naltrexone Implant (OLANI) Pharmacokinetic (PK)/Safety Study in Healthy Volunteers\", '', 'COMPLETED', 'Opioid Use Disorder', 'DRUG: naltrexone implant', 'Go Medical Industries Pty Ltd', 'National Institute on Drug Abuse (NIDA)|New York State Psychiatric Institute|Columbia University|Clinilabs, Inc.', '20.0', 'INDUSTRY', 'INTERVENTIONAL', 'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE', '2019-04-11', '2021-03-22']\n['NCT01246895', 'Follow-Up Study Evaluating The Long Term Safety and Efficacy of BST-CarGel and Microfracture Repair of the Knee', '', 'COMPLETED', 'Knee Injuries', 'DEVICE: Microfracture with BST-CarGel|DEVICE: Microfracture without BST-CarGel', 'Piramal Healthcare Canada Ltd', '', '67.0', 'INDUSTRY', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2011-03', '2014-03']\n['NCT02666495', 'Individual Schema-mode Therapy for Anorexia Nervosa: a Pilot Case Series', '', 'UNKNOWN', 'Anorexia Nervosa', 'OTHER: Psychological Therapy - Schema Therapy', 'NHS Lothian', '', '15.0', 'OTHER_GOV', 'INTERVENTIONAL', 'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT', '2016-01', '2019-01']\n['NCT01501695', 'Phase III Study of 5LGr to Treat Tic Disorder', '5LGr', 'COMPLETED', 'Tic Disorder|Tourette Syndrome|Chronic Tic Disorder', 'DRUG: 5LGr|DRUG: tiapride|DRUG: placebo', 'Tasly Pharmaceuticals, Inc.', '', '603.0', 'INDUSTRY', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT', '2008-01', '2011-10']\n['NCT02132195', 'Adrenocorticotropic Hormone (ACTH) for Frequently Relapsing and Steroid Dependent Nephrotic Syndrome', '', 'COMPLETED', 'Nephrotic Syndrome', 'DRUG: ACTH', 'Emory University', 'Mallinckrodt', '31.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT', '2014-05', '2018-03']\n['NCT02409095', 'Study Comparing DTP-HB-Hib by Disposable-Syringe Jet Injector To Vaccination By Needle And Syringe In Infants', '', 'TERMINATED', 'Immune Response to DTP-HB-Hib Vaccine', 'BIOLOGICAL: DTP-HB-Hib vaccine|DEVICE: Disposable Syringe Jet Injector (DSJI)|OTHER: Needle & Syringe', 'Serum Institute of India Pvt. Ltd.', 'PATH', '211.0', 'INDUSTRY', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION', '2015-01', '2016-03']\n['NCT05031195', 'Prognostic Impact of NLR, PLR, and MPV in Patients Undergoing AAA Open Repair', '', 'COMPLETED', 'Abdominal Aortic Aneurysm', 'OTHER: 1st tertile, 2nd tertile, 3rd tertile', 'Gangnam Severance Hospital', '', '334.0', 'OTHER', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2020-01-11', '2021-03-30']\n['NCT03737695', 'Clinical Information and Biospecimen Collection From Patients With Recurrent or Stage IV Breast Cancer', '', 'RECRUITING', 'Anatomic Stage IV Breast Cancer AJCC v8|Invasive Breast Carcinoma|Metastatic Breast Carcinoma|Peritoneal Effusion|Recurrent Breast Carcinoma', 'PROCEDURE: Biospecimen Collection|OTHER: Medical Chart Review', 'Mayo Clinic', 'National Cancer Institute (NCI)', '300.0', 'OTHER', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2019-09-16', '2024-11-15']\n['NCT00568295', 'A Four-Week Study Comparing Acetaminophen Extended Release and Rofecoxib in the Treatment of Osteoarthritis of the Knee', '', 'COMPLETED', 'Osteoarthritis of the Knee', 'DRUG: acetaminophen|DRUG: Rofecoxib|DRUG: Rofecoxib', 'Johnson & Johnson Consumer and Personal Products Worldwide', '', '403.0', 'INDUSTRY', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT', '1999-10', '2000-10']\n['NCT01891695', 'OPSCC N0 Nodal Control With Reduced IMRT', '', 'TERMINATED', 'Oropharyngeal Squamous Cell Carcinoma (OPSCCA)|HPV (Human Papillomavirus)-Associated', 'RADIATION: 39.6 Gy radiation', 'Paul W. Read, MD', '', '1.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT', '2013-10', '2016-12']\n['NCT02058095', 'Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Diastolic Cardiomyopathy (Aim3)', 'Aim 3', 'COMPLETED', 'Cardiomyopathy|Renal Impairment', 'DRUG: Tadalafil|DRUG: Placebo', 'Mayo Clinic', '', '22.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE', '2014-03', '2019-12']\n['NCT04205695', 'Comparison of Catheters Orifice Configuration For Continuous Infraclavicular Analgesia', '', 'COMPLETED', 'Pain, Postoperative|Catheter Blockage|Anesthesia', 'PROCEDURE: CEMP (closed-ended multiport catheter) group|PROCEDURE: OESP (open-ended single port catheter) group|PROCEDURE: Patient-controlled analgesia', 'Gulhane School of Medicine', '', '70.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT', '2019-12-10', '2020-02-28']\n['NCT00417495', 'Sentinel Lymph Node Technique in Multifocal Breast Cancer', '', 'COMPLETED', 'Breast Cancer', 'BEHAVIORAL: Sentinel Lymph Node Technique', 'Centre Oscar Lambret', '', '216.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC', '2006-03', '2008-09']\n['NCT02893995', 'Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® Dose Titration in Pulmonary Arterial Hypertension', '', 'WITHDRAWN', 'Pulmonary Arterial Hypertension', 'DRUG: Slow Dose Titration Group of Subcutaneous Treprostinil|DRUG: Rapid Dose Titration Group of Subcutaneous Treprostinil', 'United Therapeutics', 'CVie Therapeutics Co. Ltd.', '0.0', 'INDUSTRY', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT', '2017-02', '2018-04']\n['NCT03469895', 'Autoimmune Cytopenia and BcR Inhibitors', 'CABRI', 'UNKNOWN', 'Autoimmune Cytopenia Associated With Chronic Lymphocytic Leukemia', 'DRUG: ibrutinib ou idelalisib', 'Institut Paoli-Calmettes', 'CHU de Reims', '40.0', 'OTHER', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2017-07-21', '2018-07']\n['NCT03269695', 'Efficacy, Safety and Tolerability of PF-06687234 as Add-on Therapy to Infliximab in Active UC Subjects Not in Remission.', '', 'TERMINATED', 'Ulcerative Colitis', 'DRUG: PF-06687234|DRUG: Placebo', 'Pfizer', '', '20.0', 'INDUSTRY', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT', '2017-12-20', '2021-01-07']\n['NCT04001595', 'Global FKRP Registry', '', 'RECRUITING', 'LGMD2I|LGMDR9|Limb Girdle Muscular Dystrophy|Congenital Muscular Dystrophy|Muscle-Eye-Brain Disease|Walker-Warburg Syndrome|FKRP Gene Mutation', 'OTHER: Patient Registry', 'Newcastle University', 'LGMD2i Research Fund|CureLGMD2i|Ludwig-Maximilians - University of Munich', '1000.0', 'OTHER', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2013-11', '2025-12']\n['NCT00199095', 'Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia', '', 'COMPLETED', 'Adult Acute Lymphocytic Leukemia', 'DRUG: Adriamycin|DRUG: Cyclophosphamide|DRUG: Cytarabine|DRUG: Dexamethasone|DRUG: Idarubicin|DRUG: Ifosfamide|DRUG: Methotrexate|DRUG: Mercaptopurine|DRUG: VM26|DRUG: Vincristine', 'Goethe University', '', '40.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT', '1997-02', '2003-06']\n['NCT00901095', 'Can Diet- and Exercise-Induced Weight Loss Improve Asthma Control in Adults?', '', 'COMPLETED', 'Asthma|Obesity', 'BEHAVIORAL: Lifestyle intervention', 'Palo Alto Medical Foundation', 'National Heart, Lung, and Blood Institute (NHLBI)|Kaiser Permanente|Stanford University', '330.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH', '2010-02', '2014-03']\n['NCT02255695', 'Effects of a School-based Exercise Program on Posture, Trunk Range of Motion, and Musculoskeletal Pain', '', 'COMPLETED', 'Musculoskeletal and Connective Tissue Disorders', 'OTHER: School-based exercise program', 'Universidade Federal de Sao Carlos', 'Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.|Conselho Nacional de Desenvolvimento Científico e Tecnológico', '300.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT', '2008-12', '2012-12']\n['NCT03070795', 'Outcomes of Early Versus Delayed Oral Feeding After Cesarean Section in Korle-bu Teaching Hospital', '', 'UNKNOWN', 'Cesarean Section Complications', 'PROCEDURE: early feeding|PROCEDURE: delayed feeding', 'University of Ghana Medical School', '', '170.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH', '2017-02-23', '2017-08-20']\n['NCT03723395', 'A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib', '', 'COMPLETED', 'Drug-drug Interaction', 'DRUG: tucatinib|DRUG: itraconazole|DRUG: rifampin|DRUG: gemfibrozil|DRUG: repaglinide|DRUG: tolbutamide|DRUG: midazolam|DRUG: digoxin', 'Seagen Inc.', '', '116.0', 'INDUSTRY', 'INTERVENTIONAL', 'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT', '2018-09-17', '2018-12-28']\n['NCT04080895', 'Pharmacokinetic Study of Artemether-lumefantrine and Amodiaquine in Healthy Subjects', 'ALAQ', 'RECRUITING', 'Pharmacokinetic|Healthy|Drug Combination', 'DRUG: Artemether-lumefantrine|DRUG: Amodiaquine|DRUG: Artemether-lumefantrine|DRUG: Artemether-lumefantrine + Amodiaquine', 'University of Oxford', 'Mahidol University|Mahidol Oxford Tropical Medicine Research Unit', '16.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT', '2022-11-01', '2023-08-31']\n['NCT03049995', 'Stress Echo 2020 - The International Stress Echo Study', 'SE2020', 'UNKNOWN', 'Coronary Artery Disease|Heart Failure|Hypertrophic Cardiomyopathy|Aortic Valve Disease|Athletes Heart|Tetralogy of Fallot|Pulmonary Arterial Hypertension', 'PROCEDURE: Left ventricular contractile reserve SE|PROCEDURE: B-lines SE|PROCEDURE: Left ventricular outflow tract gradient SE|PROCEDURE: Diastolic function SE|PROCEDURE: Mitral regurgitation SE|PROCEDURE: Pulmonary hemodynamics SE|PROCEDURE: Coronary flow reserve SE', 'Fatebenefratelli Hospital', \"Institute of Clinical Physiology, CNR, Pisa,Italy|Salerno Hospital, Italy|Monaldi Hospital, Napoli, Italy|University of Pisa, Italy|San Luca Hospital, Lucca, Italy|Careggi University Hospital, Florence, Italy|Federico II University|San Carlo Public Hospital, Potenza, Italy|Royal Brompton & Harefield NHS Foundation Trust|Ospedale dell'Angelo, Venezia-Mestre|University of Parma|Hospital Clinics, Trieste, Italy|Federal University of Rio Grande do Sul|Hospital San José, Criciuma, Brasil|Hospital San Vicente de Paulo, Passo Fundo, Brasil|University of Belgrade|University of Szeged, Hungary|Elisabeth Hospital, Hodmezovasarhely, Hungary|Sandro Pertini Hospital, Rome, Italy|Hospital Clinics, Bari, Italy|Ospedale Nottola, Siena, Italy|University of Catania, Italy|Medika Cardiocenter, Saint Petersburg, Russian Federation|Acibadem City Clinic Tokuda Hospital|Investigaciones Medicas, Buenos Aires, Argentina|Tomsk National Research Scientific Centre of Russian Academy of Sciences, Tomsk, Russian Federation|Instituto Nacional de Cardiología Mexico City, Mexico|Hamad Medical Corporation, Heart Hospital -Doha-Qatar\", '300.0', 'OTHER', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2016-11', '2021-12']\n['NCT06073795', 'Ultrasongraphy Versus Fluoroscopy in Lumber Sympathetic Block in Chronic Lower Limb Ischemia', '', 'NOT_YET_RECRUITING', 'L L Ischemia', 'PROCEDURE: sympathetic block', 'Assiut University', '', '60.0', 'OTHER', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2023-11-01', '2025-12-01']\n['NCT04564495', 'Home Based Tele-exercise for People With Chronic Neurological Impairments', 'Telex', 'ACTIVE_NOT_RECRUITING', 'Neurologic Disorder|Stroke|Spinal Cord Injuries|Cerebral Palsy|Hemiplegia|Hemiparesis|Multiple Sclerosis|Parkinson Disease|Trauma, Brain|Transverse Myelitis|Friedreich Ataxia', 'BEHAVIORAL: Seated exercise', 'Burke Medical Research Institute', '', '60.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT', '2021-01-22', '2024-12-31']\n['NCT01811095', 'A Randomized Controlled Trial of a Robotic Simulation Curriculum to Teach Robotic Suturing', '', 'COMPLETED', 'Neoplasms', 'OTHER: Training', 'McGill University', '', '27.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: ', '2013-03', '2013-06']\n['NCT04470895', 'Impact of Drugs on the Risk of Falls in the Fracture Department of the Paris Saint-Joseph Hospital Group', '', 'WITHDRAWN', 'Fracture|Fall', 'DIAGNOSTIC_TEST: Failure Track patients analysis', 'Fondation Hôpital Saint-Joseph', '', '0.0', 'OTHER', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2021-09-24', '2021-09-24']\n['NCT04877795', 'Copeptin and HFABP in Cardiac Surgery', 'PRACTICE', 'UNKNOWN', 'Coronary Artery Disease|Valvular Heart Disease', 'DIAGNOSTIC_TEST: Blood sampling', 'Heinrich-Heine University, Duesseldorf', '', '700.0', 'OTHER', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2021-04-01', '2023-06-30']\n['NCT00804895', 'Cluster Headache Cortivazol Injection (CHCI)', 'CHCI', 'COMPLETED', 'Cluster Headache', 'DRUG: ALTIM, cortivazol injections|DRUG: PROAMP, subcutaneous serum physiological saline|DRUG: Verapamil', 'Assistance Publique - Hôpitaux de Paris', '', '43.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT', '2008-12', '2009-10']\n['NCT03053895', 'Bedside Versus Operating Room Burr-Hole Drainage of Chronic Subdural Hematoma (DECIDE)', 'DECIDE', 'UNKNOWN', 'Chronic Subdural Hematoma', 'PROCEDURE: CSDH - Bedside twist drill technique|PROCEDURE: CSDH - Operating Room Burr-hole technique', 'Hamilton Health Sciences Corporation', '', '486.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT', '2017-04-01', '2020-02-28']\n['NCT02782195', 'Evaluation of Gut Absorption Rate of Glucose After a Large Evening Meal in Type 1 Diabetes', '', 'COMPLETED', 'Type 1 Diabetes', '', 'University of Cambridge', 'Cambridge University Hospitals NHS Foundation Trust', '16.0', 'OTHER', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2008-11', '2011-06']\n['NCT00843895', 'Multicenter Prospective Evaluation of the Incidence and Serotyes of Invasive Pneumoccocal Disease (IPD) Among Children Below 5 Years', 'Pneumococci', 'UNKNOWN', 'Pneumococcal Disease', 'BIOLOGICAL: pneumococcal conjugate vaccine(prevenar)', 'King Saud University', '', '400.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SCREENING', '2009-03', '2009-12']\n['NCT05393895', 'An Evaluation of the Safety of CSF-1 in Presbyopic Subjects', '', 'COMPLETED', 'Presbyopia', 'DRUG: CSF-1|DRUG: Vehicle', 'Orasis Pharmaceuticals Ltd.', '', '178.0', 'INDUSTRY', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT', '2022-04-22', '2022-12-01']\n['NCT00145795', 'A Research Study to See if a Change in Therapy for HIV Infection Can Improve the Immune Response to Treatment', '', 'COMPLETED', 'HIV Infections', 'DRUG: Kaletra + Current Dual NRTI Backbone|DRUG: Current Regimen', 'University of Chicago', 'Abbott', '20.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT', '2004-04', '2009-12']\n['NCT06182995', 'Anticipating Decline and Providing Therapy', 'ADAPT', 'NOT_YET_RECRUITING', 'Cognitive Impairment|Dementia|Post ICU Syndrome|Critical Illness|Cognitive Impairment, Mild', 'BEHAVIORAL: Usual Care post-Intensive Care Unit (ICU)|BEHAVIORAL: Anticipating Decline and Providing Therapy (ADAPT)', 'Wake Forest University Health Sciences', 'National Institute on Aging (NIA)', '120.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE', '2024-03', '2027-03']\n['NCT04061395', 'Guselkumab for Hidradenitis Suppurativa, a Mode of Action Study.', 'HiGUS', 'UNKNOWN', 'Hidradenitis Suppurativa', 'BIOLOGICAL: Guselkumab', 'Barbara Horváth, Principal Investigator', 'Janssen-Cilag Ltd.', '20.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER', '2019-09', '2020-12']\n['NCT04114695', 'Aortic Calcification and Central Blood Pressure in Patients With Chronic Kidney Disease', 'ACCEPT', 'COMPLETED', 'Arterial Calcification|Kidney Diseases|Coronary Artery Disease|Aortic Calcification|Stroke|Vascular Diseases|Vascular Calcification', '', 'Central Jutland Regional Hospital', '', '185.0', 'OTHER', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2019-10-15', '2022-01-01']\n['NCT01170195', 'Effectiveness of Licorice Extract Dietary Supplement on the Treatment of Postmenopausal Symptoms', '', 'UNKNOWN', 'Postmenopausal Symptoms|Vaginal Dryness', 'DIETARY_SUPPLEMENT: Calmera-Licorice Root Extract (Licogen)', 'F&C Licorice Ltd', '', '120.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT', '2010-09', '2011-09']\n['NCT05409495', 'Titanium-prepared Platelet-rich Fibrin in Periodontal Regeneration', '', 'COMPLETED', 'Platelet-Rich Fibrin', 'PROCEDURE: periodontal surgical procedure (open flap debridement)|PROCEDURE: periodontal surgical procedure (OFD +autogenous Titanium-prepared platelet-rich fibrin (OFD+ T-PRF))', 'Ataturk University', '', '20.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT', '2021-04-01', '2022-02-15']\n['NCT05360095', 'Comparing Game Facilitated Interactivity to Genetic Counseling for Prenatal Screening Education', '', 'RECRUITING', 'Genetic Counseling|Shared Decision Making|Pregnancy|Genetic Testing|Prenatal Disorder', 'BEHAVIORAL: Meaning of Screening|BEHAVIORAL: Genetic Counseling|BEHAVIORAL: Usual Care', 'Erin Rothwell', 'National Human Genome Research Institute (NHGRI)', '1125.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH', '2023-03-07', '2025-12']\n['NCT02574195', 'Evolution of Effectiveness of Diabetes Medical Care in Russia', '', 'COMPLETED', 'Diabetes Mellitus, Type 2|Diabetes Mellitus, Type 1', '', 'Endocrinology Research Centre, Moscow', '', '599.0', 'OTHER_GOV', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2015-08', '2015-10']\n['NCT02975895', 'Outcome of Different IOLs in Patients With and Without Uveitis', '', 'COMPLETED', 'Uveitis|Cataract|Inflammation|Posterior Capsule Opacification', 'DEVICE: Hydrophobic IOL: Vivinex (HOYA)|DEVICE: Hydrophilic IOL: INCISE (Bausch+Lomb)', 'Vastra Gotaland Region', '', '56.0', 'OTHER_GOV', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT', '2016-12-30', '2022-03-17']\n['NCT03332095', 'Evaluating the Pharmacokinetics, Safety, and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents', '', 'COMPLETED', 'HIV Infections', 'DRUG: Doravirine (DOR)|DRUG: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF)|DRUG: Antiretroviral (ARV) medications', 'National Institute of Allergy and Infectious Diseases (NIAID)', '', '55.0', 'NIH', 'INTERVENTIONAL', 'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT', '2018-07-02', '2022-05-25']\n['NCT05191095', 'The Accuracy of Human Endoscopic Detection of Submucosal Invasive Cancer in Colorectal Polyps', '', 'COMPLETED', 'Colorectal Polyp', '', 'University Hospital, Ghent', '', '82.0', 'OTHER', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2021-03-01', '2021-06-01']\n['NCT01388595', 'Fluticasone and Salmeterol in Allergic Rhinitis', '', 'COMPLETED', 'Allergic Rhinitis', 'DRUG: FLUTICASONE PROPRIONATE|DRUG: Salmeterol|DRUG: PLACEBO', 'University of Dundee', '', '23.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT', '2006-11', '2010-10']\n['NCT00382395', 'SOLX Gold Shunt Versus Control Implant: Randomized Trial for Refractory Glaucoma', '', 'SUSPENDED', 'Glaucoma|Glaucoma, Open Angle', 'DEVICE: SOLX Gold Shunt GMS-plus|DEVICE: Ahmed FP7 Glaucoma Valve', 'SOLX, Inc.', '', '180.0', 'INDUSTRY', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT', '2005-11', '2017-07']\n"
     ]
    }
   ],
   "source": [
    "cleanedData = cleanRDD.collect()\n",
    "for row in cleanedData:\n",
    "    print(row)\n",
    "def clean_row(row):\n",
    "    if len(row) < 14:\n",
    "        return row \n",
    "    row = row[:5] + [intervention for field in row[5].split('|') for intervention in field.split(':')] + row[6:]\n",
    "    row = row[:7] + [collaborator.strip() for collaborator in row[7].split('|')] + row[8:] if row[7] else row[:7] + [] + row[8:]\n",
    "    row = row[:11] + [design for field in row[11].split('|') for design in field.split(':')] + row[12:]\n",
    "\n",
    "    return row"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "1e80eb85-26bf-4bc3-aa2c-6263b5cadc49",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [],
   "source": [
    "header = cleanRDD.first()\n",
    "cleanheaderRDD=cleanRDD.filter(lambda row: row != header)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "8938960b-5aa3-4f19-8716-0de1cb04f5c6",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Out[13]: [['NCT03630471',\n  'Effectiveness of a Problem-solving Intervention for Common Adolescent Mental Health Problems in India',\n  'PRIDE',\n  'COMPLETED',\n  'Mental Health Issue (E.G., Depression, Psychosis, Personality Disorder, Substance Abuse)',\n  \"BEHAVIORAL: PRIDE 'Step 1' problem-solving intervention|BEHAVIORAL: Enhanced usual care\",\n  'Sangath',\n  'Harvard Medical School (HMS and HSDM)|London School of Hygiene and Tropical Medicine',\n  '250.0',\n  'OTHER',\n  'INTERVENTIONAL',\n  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n  '2018-08-20',\n  '2019-02-28'],\n ['NCT05992571',\n  'Oral Ketone Monoester Supplementation and Resting-state Brain Connectivity',\n  '',\n  'RECRUITING',\n  'Cerebrovascular Function|Cognition',\n  'OTHER: Placebo|DIETARY_SUPPLEMENT: β-OHB',\n  'McMaster University',\n  \"Alzheimer's Society of Brant, Haldimand Norfolk, Hamilton Halton\",\n  '30.0',\n  'OTHER',\n  'INTERVENTIONAL',\n  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE',\n  '2023-10-25',\n  '2024-08'],\n ['NCT00237471',\n  'Impact of Tight Glycaemic Control in Acute Myocardial Infarction',\n  '',\n  'TERMINATED',\n  'Myocardial Infarct|Hyperglycemia',\n  'DRUG: Insulin (tight blood glucose control)',\n  'Melbourne Health',\n  'National Health and Medical Research Council, Australia|Bristol-Myers Squibb',\n  '40.0',\n  'OTHER',\n  'INTERVENTIONAL',\n  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n  '2005-10',\n  '2006-05'],\n ['NCT03820271',\n  'New Prognostic Predictive Models of Mortality of Decompensated Cirrhotic Patients Waiting for Liver Transplantation',\n  'SUPERMELD',\n  'RECRUITING',\n  'Decompensated Cirrhosis|Liver Transplantation',\n  'OTHER: SuperMELD',\n  'Assistance Publique - Hôpitaux de Paris',\n  '',\n  '500.0',\n  'OTHER',\n  'INTERVENTIONAL',\n  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER',\n  '2020-10-01',\n  '2023-10-01'],\n ['NCT06229171',\n  'InTake Care: Development and Validation of an Innovative, Personalized Digital Health Solution for Medication Adherence Support in Cardiovascular Prevention',\n  'InTakeCare',\n  'NOT_YET_RECRUITING',\n  'Hypertension|Treatment Adherence and Compliance|Digital Health',\n  'OTHER: adherence support system based on a vocal assistant',\n  'Istituto Auxologico Italiano',\n  'Istituti Clinici Scientifici Maugeri SpA|Politecnico di Milano',\n  '206.0',\n  'OTHER',\n  'INTERVENTIONAL',\n  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER',\n  '2024-10-01',\n  '2026-04-01']]"
     ]
    }
   ],
   "source": [
    "cleanheaderRDD.take(5)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "fc5f73f9-dde3-41e8-aa48-b43f76fac254",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Number of distinct studies: 483421\n"
     ]
    }
   ],
   "source": [
    "from pyspark.sql.types import *\n",
    "from pyspark.sql.functions import *\n",
    "#defining the schema \n",
    "schema = StructType([\n",
    "    StructField(\"_1\", StringType(), True),\n",
    "    StructField(\"_2\", StringType(), True),\n",
    "    StructField(\"_3\", StringType(), True),\n",
    "    StructField(\"_4\", StringType(), True),\n",
    "    StructField(\"_5\", StringType(), True),\n",
    "    StructField(\"_6\", StringType(), True),\n",
    "    StructField(\"_7\", StringType(), True),\n",
    "    StructField(\"_8\", StringType(), True),\n",
    "    StructField(\"_9\", StringType(), True),\n",
    "    StructField(\"_10\", StringType(), True),\n",
    "    StructField(\"_11\", StringType(), True),\n",
    "    StructField(\"_12\", StringType(), True),\n",
    "    StructField(\"_13\", StringType(), True),\n",
    "    StructField(\"_14\", StringType(), True)\n",
    "])\n",
    "def create_row(row):\n",
    "    if len(row) < 14:\n",
    "        return None  \n",
    "    return Row(*row)\n",
    "cleandf = cleanRDD.map(create_row).filter(lambda x: x is not None).toDF(schema)\n",
    "\n",
    "\n",
    "distinct_studies = cleandf.select('_1').distinct().count()\n",
    "\n",
    "print(f\"Number of distinct studies: {distinct_studies}\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "025202ab-2166-4b20-98d4-63cb6f1133ee",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "+-----------+--------------------+---------+----------+--------------------+--------------------+--------------------+--------------------+----------+-----------+--------------+--------------------+----------+----------+\n|         Id|         Study Title|  Acronym|    Status|          Conditions|       Interventions|             Sponsor|       Collaborators|Enrollment|Funder Type|          Type|        Study Design|     Start|Completion|\n+-----------+--------------------+---------+----------+--------------------+--------------------+--------------------+--------------------+----------+-----------+--------------+--------------------+----------+----------+\n|         Id|         Study Title|  Acronym|    Status|          Conditions|       Interventions|             Sponsor|       Collaborators|Enrollment|Funder Type|          Type|        Study Design|     Start|Completion|\n|NCT03630471|Effectiveness of ...|    PRIDE| COMPLETED|Mental Health Iss...|BEHAVIORAL: PRIDE...|             Sangath|Harvard Medical S...|     250.0|      OTHER|INTERVENTIONAL|Allocation: RANDO...|2018-08-20|2019-02-28|\n|NCT05992571|Oral Ketone Monoe...|         |RECRUITING|Cerebrovascular F...|OTHER: Placebo|DI...| McMaster University|Alzheimer's Socie...|      30.0|      OTHER|INTERVENTIONAL|Allocation: RANDO...|2023-10-25|   2024-08|\n|NCT00237471|Impact of Tight G...|         |TERMINATED|Myocardial Infarc...|DRUG: Insulin (ti...|    Melbourne Health|National Health a...|      40.0|      OTHER|INTERVENTIONAL|Allocation: RANDO...|   2005-10|   2006-05|\n|NCT03820271|New Prognostic Pr...|SUPERMELD|RECRUITING|Decompensated Cir...|    OTHER: SuperMELD|Assistance Publiq...|                    |     500.0|      OTHER|INTERVENTIONAL|Allocation: NA|In...|2020-10-01|2023-10-01|\n+-----------+--------------------+---------+----------+--------------------+--------------------+--------------------+--------------------+----------+-----------+--------------+--------------------+----------+----------+\nonly showing top 5 rows\n\n"
     ]
    }
   ],
   "source": [
    "cleandf= cleandf.withColumnRenamed(\"_1\", \"Id\").\\\n",
    "    withColumnRenamed(\"_2\", \"Study Title\").\\\n",
    "    withColumnRenamed(\"_3\", \"Acronym\").\\\n",
    "    withColumnRenamed(\"_4\", \"Status\").\\\n",
    "    withColumnRenamed(\"_5\", \"Conditions\").\\\n",
    "    withColumnRenamed(\"_6\", \"Interventions\").\\\n",
    "    withColumnRenamed(\"_7\", \"Sponsor\").\\\n",
    "    withColumnRenamed(\"_8\", \"Collaborators\").\\\n",
    "    withColumnRenamed(\"_9\", \"Enrollment\").\\\n",
    "    withColumnRenamed(\"_10\", \"Funder Type\").\\\n",
    "    withColumnRenamed(\"_11\", \"Type\").\\\n",
    "    withColumnRenamed(\"_12\", \"Study Design\").\\\n",
    "    withColumnRenamed(\"_13\",\"Start\").\\\n",
    "    withColumnRenamed(\"_14\", \"Completion\")\n",
    "\n",
    "cleandf.show(5)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "173fb18a-d560-42df-bc3a-330a6c667f7b",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Out[16]: [FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2023/', name='clinicaltrial_2023/', size=0, modificationTime=0),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2023-1.zip', name='clinicaltrial_2023-1.zip', size=57166668, modificationTime=1713832661000),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2023.csv', name='clinicaltrial_2023.csv', size=292436366, modificationTime=1714515227000),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2023.zip', name='clinicaltrial_2023.zip', size=57166668, modificationTime=1712589310000),\n FileInfo(path='dbfs:/FileStore/tables/pharma-1.zip', name='pharma-1.zip', size=109982, modificationTime=1713832611000),\n FileInfo(path='dbfs:/FileStore/tables/pharma.csv/', name='pharma.csv/', size=0, modificationTime=0),\n FileInfo(path='dbfs:/FileStore/tables/pharma.zip', name='pharma.zip', size=109982, modificationTime=1712589332000),\n FileInfo(path='dbfs:/FileStore/tables/steam_200k-1.csv', name='steam_200k-1.csv', size=8059447, modificationTime=1714157236000),\n FileInfo(path='dbfs:/FileStore/tables/steam_200k-2.csv', name='steam_200k-2.csv', size=8059447, modificationTime=1714337658000),\n FileInfo(path='dbfs:/FileStore/tables/steam_200k.csv', name='steam_200k.csv', size=8059447, modificationTime=1713124868000)]"
     ]
    }
   ],
   "source": [
    "dbutils.fs.ls(\"/FileStore/tables/\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "69289856-4dc5-4851-9d7a-8d74dcfbe48f",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Out[17]: True"
     ]
    }
   ],
   "source": [
    "dbutils.fs.cp(\"/FileStore/tables/pharma.zip\", \"file:/tmp/\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "0573a188-f0be-4be4-937f-3b14e394147a",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Rserv\nRtmp1EUY0n\nchauffeur-daemon-params\nchauffeur-daemon.pid\nchauffeur-env.sh\nclinicaltrial_2023.zip\ncustom-spark.conf\ndriver-daemon-params\ndriver-daemon.pid\ndriver-env.sh\nhsperfdata_root\npharma.zip\npython_lsp_logs\nsystemd-private-cd7aa280e67e429f85a0ae2cca21a4dc-apache2.service-MUpfHg\nsystemd-private-cd7aa280e67e429f85a0ae2cca21a4dc-ntp.service-yxq2vh\nsystemd-private-cd7aa280e67e429f85a0ae2cca21a4dc-systemd-logind.service-QqVD6g\nsystemd-private-cd7aa280e67e429f85a0ae2cca21a4dc-systemd-resolved.service-0WSoAf\ntmp.jT9xtZh66L\n"
     ]
    }
   ],
   "source": [
    "%sh\n",
    "ls /tmp/"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "74741d6b-9928-4abc-9c37-caf4619475d2",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Archive:  /tmp/pharma.zip\n  inflating: /tmp/pharma.csv         \n"
     ]
    }
   ],
   "source": [
    "%sh\n",
    "unzip -d /tmp/ /tmp/pharma.zip"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "1bb403c5-0bc8-454b-9420-10685a483a00",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "/tmp/pharma.csv\n"
     ]
    }
   ],
   "source": [
    "%sh\n",
    "ls /tmp/pharma.csv"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "d9593363-245f-467a-9d94-f86ff02f1b14",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Out[21]: True"
     ]
    }
   ],
   "source": [
    "dbutils.fs.mkdirs(\"FileStore/tables/pharma.csv\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "20ccc719-0122-4e39-aac6-5ab03146067d",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Out[22]: True"
     ]
    }
   ],
   "source": [
    "dbutils.fs.mv(\"file:/tmp/pharma.csv\", \"/FileStore/tables/pharma.csv\", True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "3c1c2ad5-f2e6-4fea-acc2-c969fa5629c5",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Out[23]: [FileInfo(path='dbfs:/FileStore/tables/pharma.csv/pharma.csv', name='pharma.csv', size=678999, modificationTime=1714515390000)]"
     ]
    }
   ],
   "source": [
    "dbutils.fs.ls(\"FileStore/tables/pharma.csv/\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "3b21f226-380e-4a23-8ba0-3fc9fde2d2c6",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['Id', 'Study Title', 'Acronym', 'Status', 'Conditions', 'Interventions', 'Sponsor', 'Collaborators', 'Enrollment', 'Funder Type', 'Type', 'Study Design', 'Start', 'Completion']\n['NCT03630471', 'Effectiveness of a Problem-solving Intervention for Common Adolescent Mental Health Problems in India', 'PRIDE', 'COMPLETED', 'Mental Health Issue (E.G., Depression, Psychosis, Personality Disorder, Substance Abuse)', \"BEHAVIORAL: PRIDE 'Step 1' problem-solving intervention|BEHAVIORAL: Enhanced usual care\", 'Sangath', 'Harvard Medical School (HMS and HSDM)|London School of Hygiene and Tropical Medicine', '250.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT', '2018-08-20', '2019-02-28']\n['NCT05992571', 'Oral Ketone Monoester Supplementation and Resting-state Brain Connectivity', '', 'RECRUITING', 'Cerebrovascular Function|Cognition', 'OTHER: Placebo|DIETARY_SUPPLEMENT: β-OHB', 'McMaster University', \"Alzheimer's Society of Brant, Haldimand Norfolk, Hamilton Halton\", '30.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE', '2023-10-25', '2024-08']\n['NCT00237471', 'Impact of Tight Glycaemic Control in Acute Myocardial Infarction', '', 'TERMINATED', 'Myocardial Infarct|Hyperglycemia', 'DRUG: Insulin (tight blood glucose control)', 'Melbourne Health', 'National Health and Medical Research Council, Australia|Bristol-Myers Squibb', '40.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT', '2005-10', '2006-05']\n['NCT03820271', 'New Prognostic Predictive Models of Mortality of Decompensated Cirrhotic Patients Waiting for Liver Transplantation', 'SUPERMELD', 'RECRUITING', 'Decompensated Cirrhosis|Liver Transplantation', 'OTHER: SuperMELD', 'Assistance Publique - Hôpitaux de Paris', '', '500.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER', '2020-10-01', '2023-10-01']\n['NCT06229171', 'InTake Care: Development and Validation of an Innovative, Personalized Digital Health Solution for Medication Adherence Support in Cardiovascular Prevention', 'InTakeCare', 'NOT_YET_RECRUITING', 'Hypertension|Treatment Adherence and Compliance|Digital Health', 'OTHER: adherence support system based on a vocal assistant', 'Istituto Auxologico Italiano', 'Istituti Clinici Scientifici Maugeri SpA|Politecnico di Milano', '206.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER', '2024-10-01', '2026-04-01']\n['NCT02945371', 'Tailored Inhibitory Control Training to Reverse EA-linked Deficits in Mid-life', 'REV', 'COMPLETED', 'Smoking|Alcohol Drinking|Prescription Drug Abuse|Substance-Related Disorders|Oral Intake Reduced', 'BEHAVIORAL: Person-centered inhibitory control training|BEHAVIORAL: Active behavioral response training', 'University of Oregon', '', '103.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION', '2014-09', '2016-05']\n['NCT01055171', 'Neuromodulation of Trauma Memories in PTSD & Alcohol Dependence', '', 'COMPLETED', 'Alcohol Dependence|PTSD', 'DRUG: Propranolol|DRUG: Placebo', 'Medical University of South Carolina', 'National Institute on Alcohol Abuse and Alcoholism (NIAAA)', '44.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT', '2010-01', '2012-08']\n['NCT01125371', 'Computerized Brief Alcohol Intervention (BI) for Binge Drinking HIV At-Risk and Infected Women', '', 'COMPLETED', 'Alcohol; Harmful Use|Binge Drinking|Risk Behavior|HIV Infection', 'BEHAVIORAL: Computerized brief alcohol intervention + IVR booster calls|BEHAVIORAL: Computerized brief alcohol intervention|BEHAVIORAL: Attention Control', 'Johns Hopkins University', 'National Institute on Alcohol Abuse and Alcoholism (NIAAA)', '439.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT', '2011-10', '2016-06-07']\n['NCT02554071', 'Manitoba Pharmacist Initiated Smoking Cessation Pilot Project', '', 'COMPLETED', 'Smoking Cessation', 'OTHER: Pharmacist - Smoking Cessation Support', 'University of Manitoba', 'Govenment of Manitoba|Canadian Foundation for Pharmacy|Neighbourhood Pharmacy Association of Canada', '119.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE', '2014-01', '2014-11']\n['NCT01772771', 'Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program', '', 'RECRUITING', 'Glioma|Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm|Melanoma|Sarcoma', 'PROCEDURE: Biospecimen Collection|OTHER: Genetic Testing|OTHER: Medical Chart Review', 'M.D. Anderson Cancer Center', 'National Cancer Institute (NCI)', '12000.0', 'OTHER', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2012-03-01', '2033-03-01']\n['NCT02633371', 'A Pilot Study Exploring the Efficacy and Safety of Topical Oxybutynin 3% Gel for Primary Focal Hyperhidrosis in Adolescents and Young Adults', '', 'COMPLETED', 'Hyperhidrosis', 'DRUG: Oxybutynin 3% gel', 'University of Colorado, Denver', 'Society for Pediatric Dermatology', '10.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT', '2016-02', '2017-05']\n['NCT03400371', 'Biology of Juvenile Myoclonic Epilepsy', 'BIOJUME', 'RECRUITING', 'Juvenile Myoclonic Epilepsy', 'OTHER: Blood draw|OTHER: Existing samples', \"King's College London\", \"King's College Hospital NHS Trust|Charles University, Czech Republic|Hopital Universitaire Robert-Debre|Vestre Viken Hospital Trust|The Hospital for Sick Children|Cardiff University|Odense University Hospital\", '1000.0', 'OTHER', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2017-07-13', '2026-06-30']\n['NCT00120471', 'Safety and Blood Levels of Tenofovir Disoproxil Fumarate in HIV Infected Pregnant Women and Their Babies', '', 'COMPLETED', 'HIV Infections', 'DRUG: Tenofovir disoproxil fumarate|DRUG: Tenofovir disoproxil fumarate|DRUG: Tenofovir disoproxil fumarate', 'National Institute of Allergy and Infectious Diseases (NIAID)', 'Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute on Drug Abuse (NIDA)|National Institute of Mental Health (NIMH)', '122.0', 'NIH', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION', '2006-11', '2011-12']\n['NCT04784871', 'Promoting Wellbeing: The Five Ways to All Intervention', '5WaysA', 'COMPLETED', 'Wellbeing|Health Attitude|Quality of Life', 'BEHAVIORAL: 5waysA Intervention|BEHAVIORAL: 5waysA Active wait-list control|BEHAVIORAL: 5waysA Inactive wait-list control', 'University of Oslo', 'Norwegian Institute of Public Health|Norwegian Council for Mental Health|The Dam Foundation', '970.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION', '2021-03-04', '2023-02-24']\n['NCT02383771', 'Reversal of the Anti-platelet Effects of Ticagrelor', 'REVERSAL', 'COMPLETED', 'Coronary Artery Disease', 'DRUG: Ticagrelor|DRUG: Aspirin + Ticagrelor|DRUG: Control|DRUG: Aspirin + Ticagrelor', 'The First Affiliated Hospital with Nanjing Medical University', 'National Natural Science Foundation of China', '64.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT', '2015-03', '2016-12']\n['NCT03269071', 'Neural Stem Cell Transplantation in Multiple Sclerosis Patients', 'STEMS', 'COMPLETED', 'Progressive Multiple Sclerosis', 'DRUG: human fetal-derived Neural Stem Cells (hNSCs)', 'IRCCS San Raffaele', 'Fondazione Italiana Sclerosi Multipla', '4.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT', '2017-05-17', '2021-07-31']\n['NCT01659671', 'RCT of the Effect of Uvulopalatopharyngoplasty Compared to Expectancy in Patients With Obstructive Sleep Apnea', 'SKUP3', 'COMPLETED', 'Obstructive Sleep Apnea Syndrome', 'PROCEDURE: Uvulopalatopharyngoplasty', 'Karolinska University Hospital', 'Karolinska Institutet', '65.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT', '2007-06', '2014-05']\n['NCT04765371', 'Comparison Between Prednisolone and Dexamethasone on Mortality in Patients on Oxygen Therapy, With CoViD-19', 'COPreDex', 'COMPLETED', 'Coronavirus Infection', 'DRUG: DEXAMETHASONE|DRUG: PREDNISOLONE', 'Hôpital NOVO', '', '89.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT', '2021-03-03', '2022-05-13']\n['NCT02830971', 'Developing a Standardized Learning Curve', '', 'COMPLETED', 'Registered Nurses|Nursing Personnel|Motor Skills', 'PROCEDURE: Doing Different ICU techniques and skills', 'Baqiyatallah Medical Sciences University', 'Shahid Beheshti University|Tehran University of Medical Sciences', '60.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE', '2016-07', '2021-04-12']\n['NCT00416871', 'Interleukin-2 and Interferon in Treating Patients With Metastatic Kidney Cancer', '', 'COMPLETED', 'Kidney Cancer', 'BIOLOGICAL: aldesleukin|BIOLOGICAL: recombinant interferon alfa', 'Centre Leon Berard', '', '220.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: |Masking: NONE|Primary Purpose: TREATMENT', '', '2006-02']\n['NCT05900271', 'Dutch-Depression Outcome Trial Comparing 5 Day Multi Daily Neuronavigated Theta Burst Sessions With 6 Weeks rTMS', 'DDOT', 'ACTIVE_NOT_RECRUITING', 'Treatment Resistant Depression', 'DEVICE: rTMS|DEVICE: iTBS', 'Amsterdam UMC, location VUmc', 'Radboud University Medical Center|University Medical Center Groningen|Maastricht University|Trimbos|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)', '108.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT', '2023-11-15', '2027-12']\n['NCT02469571', 'Modulation of Gut Microbiota in Early Sepsis: A Pilot Study', 'MGM-sepsis', 'COMPLETED', 'Sepsis', 'DIETARY_SUPPLEMENT: Winclove 607|DIETARY_SUPPLEMENT: Placebo', 'Medical University of Graz', '', '15.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION', '2015-09-01', '2018-03-01']\n['NCT05807971', 'Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ATH-063 in Healthy Subjects', '', 'RECRUITING', 'Inflammatory Bowel Diseases|Crohn Disease|Ulcerative Colitis|Autoimmune Diseases', 'DRUG: ATH-063|DRUG: Placebo', 'Athos Therapeutics Inc', 'Syneos Health|Athos Therapeutics Australia Pty Ltd', '76.0', 'INDUSTRY', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT', '2023-04-06', '2024-02-08']\n['NCT02083471', \"Cow's Milk and Hen's Egg Hyposensitization in Adults\", '', 'UNKNOWN', \"Egg Allergy|Cow's Milk Allergy\", \"DIETARY_SUPPLEMENT: Specific Oral Tolerance Induction with Egg or Cow's milk\", 'Turku University Hospital', '', '40.0', 'OTHER_GOV', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT', '2015-04', '2017-05']\n['NCT01062971', 'Clinical Study of A Fixed Combination of Timolol-Brimonidine-Dorzolamide', '', 'COMPLETED', 'Primary Open Angle Glaucoma|Ocular Hypertension', 'DRUG: dorzolamide-timolol-brimonidine', 'Laboratorios Sophia S.A de C.V.', '', '124.0', 'INDUSTRY', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT', '2006-02', '2008-06']\n['NCT03928171', 'The Effect of Intra-abdominal Pressure on Peritoneal Perfusion During Laparoscopic Colorectal Surgery', 'PERFUSION', 'COMPLETED', 'Laparoscopic Surgery|Pneumoperitoneum', 'OTHER: Intra-abdominal pressure during laparoscopy', 'Radboud University Medical Center', '', '30.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT', '2018-06-13', '2018-12-24']\n['NCT00897871', 'Evaluating the Side Effects and How Well Anticancer Drugs Work in Very Young Patients With Cancer', '', 'UNKNOWN', 'Unspecified Childhood Solid Tumor, Protocol Specific', 'DRUG: carboplatin|DRUG: cyclophosphamide|DRUG: etoposide phosphate|GENETIC: gene expression analysis|GENETIC: polymorphism analysis|OTHER: pharmacological study', \"Children's Cancer and Leukaemia Group\", '', '60.0', 'OTHER', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2007-02', '']\n['NCT00848471', 'Validation of the Quark RMR Calorimeter (Cosmed) Versus Deltatrac II (GE Health Care Clinical Systems)', 'Protocol Quark', 'UNKNOWN', 'Healthy|Obesity', 'DEVICE: Quark RMR|DEVICE: Deltatrac II', 'Hospices Civils de Lyon', 'Centre de Recherche en Nutrition Humaine Rhone-Alpe', '30.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH', '2009-01', '2009-12']\n['NCT06135571', 'Study on the No.253 Lymph Node Metastasis Patterns in Left-Sided Colon and Rectal Cancer', '', 'RECRUITING', 'Colorectal Cancer|Lymph Node Metastasis', 'PROCEDURE: Laparoscopic colorectal surgery', 'Cancer Institute and Hospital, Chinese Academy of Medical Sciences', 'Peking Union Medical College Hospital|Peking University Cancer Hospital & Institute|China-Japan Friendship Hospital|Chinese PLA General Hospital', '3000.0', 'OTHER', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2023-09-01', '2026-09-01']\n['NCT01189071', 'Preoperative Use of Darifenacin (Enablex) to Alleviate Postoperative Ureteral Stent Pain', '', 'TERMINATED', 'Overactive Bladder|Renal Colic|Pain, Postoperative', 'DRUG: Darifenacin', 'University of Missouri-Columbia', '', '3.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT', '2009-08', '2011-07']\n['NCT00728871', 'The Correlations Between HPV L1-Specific Immunologic Responses in Cervical Cancer and Cervical Intraepithelial Neoplasia (CIN) Patients and Their Prognosis', '', 'UNKNOWN', 'Cervical Cancer|Cervical Intraepithelial Neoplasia', 'PROCEDURE: peripheral blood isolation', 'National Taiwan University Hospital', '', '600.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE', '2005-12', '2011-12']\n['NCT05592171', 'Occlusafe® Assisted MW Alone or With DEB-TACE Compared to MW With DEB-TACE in the Treatment of HCC', 'SEASON-HCC', 'RECRUITING', 'HCC', 'PROCEDURE: Microwave ablation + Occlusafe + DEB-TACE|PROCEDURE: Microwave ablation + Occlusafe|PROCEDURE: Microwave ablation + DEB-TACE', 'University of Pisa', 'Azienda Ospedaliera Città della Salute e della Scienza di Torino|Fondazione Policlinico Universitario Agostino Gemelli IRCCS|Azienda Ospedaliera Universitaria Policlinico|IRCCS Azienda Ospedaliero-Universitaria di Bologna|Terumo Europe N.V.|Azienda Ospedaliero, Universitaria Pisana', '60.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT', '2022-10-17', '2025-10-17']\n['NCT00520871', 'The Water-Blueberry Study', '', 'COMPLETED', 'Cardiovascular Disease', 'DRUG: Blueberry juice', 'University of Oslo', 'Ullevaal University Hospital', '62.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE|Primary Purpose: PREVENTION', '2003-03', '2004-04']\n['NCT05913271', 'Study on the Correlation Between NAT2(N-acetyltransferase2) Gene Polymorphism and CrCl(Creatine Clreance) and the Efficacy and Safety of Levosimendan in Patients With Severe Heart Failure', '', 'RECRUITING', 'Heart Failure|Levosimendan|Efficacy|Safety', '', 'Yi Han', 'Qianfoshan Hospital', '352.0', 'OTHER', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2023-05-30', '2025-05-30']\n['NCT04006171', 'Comparison of Serum C Type Natriuretic Peptide Levels Between Polycystic Ovary Syndrome Patients and Healthy Women', 'CNP', 'COMPLETED', 'Polycystic Ovary Syndrome|c Type Natriuretic Peptide|Menstrual Irregularity|Hyperandrogenism', 'DIAGNOSTIC_TEST: C type natriuretic peptide', 'Near East University, Turkey', '', '90.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC', '2019-07-15', '2020-09-01']\n['NCT04370171', 'Management of Diabetic Patients With Telemedicine in the Context of the Covid-19 Epidemic', 'TeleCoviDiab', 'COMPLETED', 'Diabetes|Covid-19', 'OTHER: care modalities|OTHER: Teleconsultation either by phone or by computer consultation', 'University Hospital, Strasbourg, France', '', '610.0', 'OTHER', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2020-05-04', '2020-05-29']\n['NCT04340271', 'The Clinical Utility of Extracorporeal Shock Wave Therapy on Burns', '', 'COMPLETED', 'Burn Scar', 'OTHER: Extracorporeal shock wave therapy|OTHER: conventional occupational therapy', 'Hangang Sacred Heart Hospital', '', '48.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT', '2020-04-15', '2020-05-31']\n['NCT03075371', 'Homeostatic and Non-homeostatic Processing of Food Cues in Anorexia Nervosa', '', 'COMPLETED', 'Anorexia Nervosa|Healthy', 'OTHER: Glucose|OTHER: Placebo', 'University of Heidelberg Medical Center', 'German Research Foundation', '85.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: BASIC_SCIENCE', '2014-09', '2019-02']\n['NCT05966571', 'Ovarian Innervation Study in Patients With Polycystic Ovary Syndrome (PCOS)', '', 'RECRUITING', 'Polycystic Ovary Syndrome', 'PROCEDURE: Ovary Biopsie', 'Albanian University', '', '50.0', 'OTHER', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2023-07-01', '2024-12-01']\n['NCT03313271', 'China Lymphoma Patient Registry Study', 'CLAP', 'RECRUITING', 'Lymphoma', '', 'Jun Zhu', 'Peking University First Hospital|Tianjin Medical University Cancer Hospital|Zhejiang Cancer Hospital|Heilongjiang Cancer Hospital|Sipai(Beijing)Network Technology Co Ltd', '5000.0', 'OTHER', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2017-05-17', '2027-08-30']\n['NCT03490071', 'Long-term Follow up of Patients With Longstanding Hip and Groin Pain', 'Lund LHGP', 'RECRUITING', 'Hip Pain Chronic', '', 'Lund University', '', '81.0', 'OTHER', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2018-01-01', '2024-12-31']\n['NCT05801471', 'Clinical Evaluation of Visual Field Change in Glaucoma: an Assessment of Different Models of Progression', '', 'RECRUITING', 'Glaucoma', '', 'Centervue SpA', '', '200.0', 'INDUSTRY', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2022-05-06', '2025-11-06']\n['NCT00266071', 'Study of the Cutaneous Microcirculation in Elderly People', '', 'UNKNOWN', 'Elderly People', 'BEHAVIORAL: Cutaneous response', 'University Hospital, Angers', '', '', 'OTHER_GOV', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2005-12', '']\n['NCT04405271', 'TAF/FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study)', '', 'UNKNOWN', 'Healthcare Workers|COVID-19|SARS-CoV 2', 'DRUG: Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet|DRUG: Placebo', 'Hospital Italiano de Buenos Aires', 'Sociedad Argentina de Infectología (SADI) (Argentine Society of Infectious Diseases)', '1378.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION', '2020-07-31', '2020-11-15']\n['NCT02121171', 'Combined Trab+Trab Versus Combined Trab+Trab With Subconjunctival Implantation of Ologen for Primary Congenital Glaucoma', '', 'UNKNOWN', 'Congenital Glaucoma', 'DEVICE: Ologen Collagen Matrix|PROCEDURE: Combined trabeculotomy-trabeculectomy', 'National Centre of Ophthalmology named after academician Zarifa Aliyeva', 'Aeon Astron Europe B.V.', '40.0', 'OTHER_GOV', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT', '2010-09', '2015-09']\n['NCT01068171', 'Developing a Diabetic Foot Ulcer Protocol', '', 'WITHDRAWN', 'Diabetic Foot Ulcers', 'OTHER: type of footwear|OTHER: collagen dressing with and without silver', 'The University of Texas Health Science Center, Houston', 'Harris County Hospital District|Baylor College of Medicine', '0.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT', '2010-05', '2012-06']\n['NCT04875871', 'Particle-based Partial Tumor Irradiation of Unresectable Bulky Tumors', 'PARTICLE-PATHY', 'RECRUITING', 'Cancer', 'RADIATION: Particle radiotherapy|DIAGNOSTIC_TEST: Magnetic resonance imaging|DIAGNOSTIC_TEST: Computertomography|DIAGNOSTIC_TEST: Copper-64-Diacetyl-bis (N4-methylthiosemicarbazone) Positron Emission Tomography-Computer Tomography (64Cu-ATSM-PET-CT)|DIAGNOSTIC_TEST: 18-F-FluorDesoxyGlukose Positron Emission Tomography-Computer Tomography (18F-FDG-PET-CT)|DIAGNOSTIC_TEST: Blood sampling', 'EBG MedAustron GmbH', 'CW-Research & Management GmbH|Medical University of Vienna|Landesklinkum Wiener Neustadt|Klinik Ottakring', '22.0', 'INDUSTRY', 'INTERVENTIONAL', 'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT', '2021-11-11', '2024-12']\n['NCT00553371', 'Follow-up Evaluation Using CT Scans in Patients Who Have Been Treated For Metastatic Testicular Cancer', '', 'UNKNOWN', 'Testicular Germ Cell Tumor', 'OTHER: biomarker analysis|PROCEDURE: computed tomography', 'Royal Marsden NHS Foundation Trust', '', '300.0', 'OTHER', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2006-04', '']\n['NCT04674371', 'German Point Prevalence Study on CVC', '', 'COMPLETED', 'Data Collection', 'OTHER: central venous catheter insertion', 'Wolfram Schummer, MD, PhD', '', '537.0', 'OTHER', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2022-05-17', '2022-05-20']\n['NCT02321371', 'Effect of Goal Directed Ammonia Lowering Therapy in Acute on Chronic Liver Failure Patients With Hepatic Encephalopathy.', '', 'COMPLETED', 'Acute-On-Chronic Liver Failure', 'DRUG: Lactulose + Rifaximin|DRUG: Lactulose', 'Institute of Liver and Biliary Sciences, India', '', '73.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT', '2014-10-19', '2016-01-31']\n['NCT02344771', 'Perioperative Endothelial Dysfunction', '', 'COMPLETED', 'Myocardial Injury', 'PROCEDURE: Elective colon cancer surgery', 'Zealand University Hospital', '', '31.0', 'OTHER', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2015-03', '2015-06']\n['NCT03354871', 'Developing Models for Fatigue Monitoring in Obstetrics and Gyne- Cology Residents Using Wearables', 'IoT4Resident', 'UNKNOWN', 'Fatigue', '', 'Hillel Yaffe Medical Center', 'International Business Machines (IBM)', '6.0', 'OTHER_GOV', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2017-11', '2018-02-28']\n['NCT02804971', 'Cardiovascular Comorbidities and Bronchiectasis', 'BRONCOCA', 'ACTIVE_NOT_RECRUITING', 'Bronchiectasis', '', 'Centre Hospitalier Intercommunal Creteil', '', '200.0', 'OTHER', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2016-10-25', '2023-12']\n['NCT04591171', 'Assessing the Feasibility of N-of-1 Trials in Children With Hypertension and Chronic Kidney Disease', '', 'COMPLETED', 'Hypertension|Chronic Kidney Diseases', 'PROCEDURE: n-of-1 trial guided clinical decision making', 'The University of Texas Health Science Center, Houston', \"Children's Hospital of Philadelphia|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)\", '9.0', 'OTHER', 'INTERVENTI\n\n*** WARNING: max output size exceeded, skipping output. ***\n\nARALLEL|Masking: NONE|Primary Purpose: TREATMENT', '2022-07-29', '2026-03-20']\n['NCT00300495', 'Study of Amiodarone Given Before Lung Surgery to Prevent Atrial Fibrillation After Lung Resection', '', 'TERMINATED', 'Atrial Fibrillation|Lung Cancer', 'DRUG: Amiodarone|OTHER: Control arm, standard care', 'Beth Israel Deaconess Medical Center', '', '19.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION', '2006-02', '2009-10-13']\n['NCT01240395', 'Mindfulness-based Cognitive Therapy for Individuals With Multiple Chemical Sensitivity', '', 'COMPLETED', 'Multiple Chemical Sensitivity', 'BEHAVIORAL: Mindfulness-based Cognitive Therapy (MBCT)', 'The Danish Research Centre for Chemical Sensitivities', '', '82.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT', '2011-09', '2013-05']\n['NCT03850795', 'HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)', '', 'ACTIVE_NOT_RECRUITING', 'Prostate Cancer Metastatic|Castration-resistant Prostate Cancer', 'DRUG: HC-1119|DRUG: Enzalutamide', 'Hinova Pharmaceuticals USA, Inc.', '', '104.0', 'INDUSTRY', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT', '2021-03-15', '2024-12-31']\n['NCT00748995', 'Neuropsychological and Mental Outcomes of Operation Iraqi Freedom (OIF): A Longitudinal Cohort Study', '', 'ACTIVE_NOT_RECRUITING', 'Stress Disorders, Post-Traumatic', '', 'VA Office of Research and Development', '', '817.0', 'FED', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2010-08-31', '2025-09-30']\n['NCT01549795', 'Liver Transplantation for Hilar Cholangiocarcinoma in Association With Neoadjuvant Radio- and Chemo-therapy', '', 'UNKNOWN', 'Hilar Cholangiocarcinoma|Primary Sclerosing Cholangitis', 'PROCEDURE: Liver transplantation|RADIATION: 45 Gy external radiations|RADIATION: Endoluminal bile duct Brachytherapy|DRUG: Capecitabine|PROCEDURE: Pre liver transplantation laparoscopic hand assisted staging', 'Azienda Ospedaliera di Padova', '', '33.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT', '2012-01', '']\n['NCT00420095', 'A Study for Patients With Diabetes Mellitus (IOPA)', 'IOPA', 'COMPLETED', 'Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2', 'DRUG: Human insulin 30/70|DRUG: Insulin lispro low mix', 'Eli Lilly and Company', '', '117.0', 'INDUSTRY', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT', '2007-01', '2008-01']\n['NCT05023395', 'Safety and Efficacy of MEE-HU Medicus', '(SEM)', 'ACTIVE_NOT_RECRUITING', 'Urinary Tract Infections', 'DRUG: MEE-HU Medicus|OTHER: Placebo', 'Dr. Ahmed Ismail', 'Theodor Bilharz Research Institute|The Cairo Kidney Center|Helwan University|Zagazig University', '200.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT', '2021-10-23', '2024-05-11']\n['NCT03810495', \"The O'Neil Long Acting Naltrexone Implant (OLANI) Pharmacokinetic (PK)/Safety Study in Healthy Volunteers\", '', 'COMPLETED', 'Opioid Use Disorder', 'DRUG: naltrexone implant', 'Go Medical Industries Pty Ltd', 'National Institute on Drug Abuse (NIDA)|New York State Psychiatric Institute|Columbia University|Clinilabs, Inc.', '20.0', 'INDUSTRY', 'INTERVENTIONAL', 'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE', '2019-04-11', '2021-03-22']\n['NCT01246895', 'Follow-Up Study Evaluating The Long Term Safety and Efficacy of BST-CarGel and Microfracture Repair of the Knee', '', 'COMPLETED', 'Knee Injuries', 'DEVICE: Microfracture with BST-CarGel|DEVICE: Microfracture without BST-CarGel', 'Piramal Healthcare Canada Ltd', '', '67.0', 'INDUSTRY', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2011-03', '2014-03']\n['NCT02666495', 'Individual Schema-mode Therapy for Anorexia Nervosa: a Pilot Case Series', '', 'UNKNOWN', 'Anorexia Nervosa', 'OTHER: Psychological Therapy - Schema Therapy', 'NHS Lothian', '', '15.0', 'OTHER_GOV', 'INTERVENTIONAL', 'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT', '2016-01', '2019-01']\n['NCT01501695', 'Phase III Study of 5LGr to Treat Tic Disorder', '5LGr', 'COMPLETED', 'Tic Disorder|Tourette Syndrome|Chronic Tic Disorder', 'DRUG: 5LGr|DRUG: tiapride|DRUG: placebo', 'Tasly Pharmaceuticals, Inc.', '', '603.0', 'INDUSTRY', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT', '2008-01', '2011-10']\n['NCT02132195', 'Adrenocorticotropic Hormone (ACTH) for Frequently Relapsing and Steroid Dependent Nephrotic Syndrome', '', 'COMPLETED', 'Nephrotic Syndrome', 'DRUG: ACTH', 'Emory University', 'Mallinckrodt', '31.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT', '2014-05', '2018-03']\n['NCT02409095', 'Study Comparing DTP-HB-Hib by Disposable-Syringe Jet Injector To Vaccination By Needle And Syringe In Infants', '', 'TERMINATED', 'Immune Response to DTP-HB-Hib Vaccine', 'BIOLOGICAL: DTP-HB-Hib vaccine|DEVICE: Disposable Syringe Jet Injector (DSJI)|OTHER: Needle & Syringe', 'Serum Institute of India Pvt. Ltd.', 'PATH', '211.0', 'INDUSTRY', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION', '2015-01', '2016-03']\n['NCT05031195', 'Prognostic Impact of NLR, PLR, and MPV in Patients Undergoing AAA Open Repair', '', 'COMPLETED', 'Abdominal Aortic Aneurysm', 'OTHER: 1st tertile, 2nd tertile, 3rd tertile', 'Gangnam Severance Hospital', '', '334.0', 'OTHER', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2020-01-11', '2021-03-30']\n['NCT03737695', 'Clinical Information and Biospecimen Collection From Patients With Recurrent or Stage IV Breast Cancer', '', 'RECRUITING', 'Anatomic Stage IV Breast Cancer AJCC v8|Invasive Breast Carcinoma|Metastatic Breast Carcinoma|Peritoneal Effusion|Recurrent Breast Carcinoma', 'PROCEDURE: Biospecimen Collection|OTHER: Medical Chart Review', 'Mayo Clinic', 'National Cancer Institute (NCI)', '300.0', 'OTHER', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2019-09-16', '2024-11-15']\n['NCT00568295', 'A Four-Week Study Comparing Acetaminophen Extended Release and Rofecoxib in the Treatment of Osteoarthritis of the Knee', '', 'COMPLETED', 'Osteoarthritis of the Knee', 'DRUG: acetaminophen|DRUG: Rofecoxib|DRUG: Rofecoxib', 'Johnson & Johnson Consumer and Personal Products Worldwide', '', '403.0', 'INDUSTRY', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT', '1999-10', '2000-10']\n['NCT01891695', 'OPSCC N0 Nodal Control With Reduced IMRT', '', 'TERMINATED', 'Oropharyngeal Squamous Cell Carcinoma (OPSCCA)|HPV (Human Papillomavirus)-Associated', 'RADIATION: 39.6 Gy radiation', 'Paul W. Read, MD', '', '1.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT', '2013-10', '2016-12']\n['NCT02058095', 'Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Diastolic Cardiomyopathy (Aim3)', 'Aim 3', 'COMPLETED', 'Cardiomyopathy|Renal Impairment', 'DRUG: Tadalafil|DRUG: Placebo', 'Mayo Clinic', '', '22.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE', '2014-03', '2019-12']\n['NCT04205695', 'Comparison of Catheters Orifice Configuration For Continuous Infraclavicular Analgesia', '', 'COMPLETED', 'Pain, Postoperative|Catheter Blockage|Anesthesia', 'PROCEDURE: CEMP (closed-ended multiport catheter) group|PROCEDURE: OESP (open-ended single port catheter) group|PROCEDURE: Patient-controlled analgesia', 'Gulhane School of Medicine', '', '70.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT', '2019-12-10', '2020-02-28']\n['NCT00417495', 'Sentinel Lymph Node Technique in Multifocal Breast Cancer', '', 'COMPLETED', 'Breast Cancer', 'BEHAVIORAL: Sentinel Lymph Node Technique', 'Centre Oscar Lambret', '', '216.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC', '2006-03', '2008-09']\n['NCT02893995', 'Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® Dose Titration in Pulmonary Arterial Hypertension', '', 'WITHDRAWN', 'Pulmonary Arterial Hypertension', 'DRUG: Slow Dose Titration Group of Subcutaneous Treprostinil|DRUG: Rapid Dose Titration Group of Subcutaneous Treprostinil', 'United Therapeutics', 'CVie Therapeutics Co. Ltd.', '0.0', 'INDUSTRY', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT', '2017-02', '2018-04']\n['NCT03469895', 'Autoimmune Cytopenia and BcR Inhibitors', 'CABRI', 'UNKNOWN', 'Autoimmune Cytopenia Associated With Chronic Lymphocytic Leukemia', 'DRUG: ibrutinib ou idelalisib', 'Institut Paoli-Calmettes', 'CHU de Reims', '40.0', 'OTHER', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2017-07-21', '2018-07']\n['NCT03269695', 'Efficacy, Safety and Tolerability of PF-06687234 as Add-on Therapy to Infliximab in Active UC Subjects Not in Remission.', '', 'TERMINATED', 'Ulcerative Colitis', 'DRUG: PF-06687234|DRUG: Placebo', 'Pfizer', '', '20.0', 'INDUSTRY', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT', '2017-12-20', '2021-01-07']\n['NCT04001595', 'Global FKRP Registry', '', 'RECRUITING', 'LGMD2I|LGMDR9|Limb Girdle Muscular Dystrophy|Congenital Muscular Dystrophy|Muscle-Eye-Brain Disease|Walker-Warburg Syndrome|FKRP Gene Mutation', 'OTHER: Patient Registry', 'Newcastle University', 'LGMD2i Research Fund|CureLGMD2i|Ludwig-Maximilians - University of Munich', '1000.0', 'OTHER', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2013-11', '2025-12']\n['NCT00199095', 'Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia', '', 'COMPLETED', 'Adult Acute Lymphocytic Leukemia', 'DRUG: Adriamycin|DRUG: Cyclophosphamide|DRUG: Cytarabine|DRUG: Dexamethasone|DRUG: Idarubicin|DRUG: Ifosfamide|DRUG: Methotrexate|DRUG: Mercaptopurine|DRUG: VM26|DRUG: Vincristine', 'Goethe University', '', '40.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT', '1997-02', '2003-06']\n['NCT00901095', 'Can Diet- and Exercise-Induced Weight Loss Improve Asthma Control in Adults?', '', 'COMPLETED', 'Asthma|Obesity', 'BEHAVIORAL: Lifestyle intervention', 'Palo Alto Medical Foundation', 'National Heart, Lung, and Blood Institute (NHLBI)|Kaiser Permanente|Stanford University', '330.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH', '2010-02', '2014-03']\n['NCT02255695', 'Effects of a School-based Exercise Program on Posture, Trunk Range of Motion, and Musculoskeletal Pain', '', 'COMPLETED', 'Musculoskeletal and Connective Tissue Disorders', 'OTHER: School-based exercise program', 'Universidade Federal de Sao Carlos', 'Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.|Conselho Nacional de Desenvolvimento Científico e Tecnológico', '300.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT', '2008-12', '2012-12']\n['NCT03070795', 'Outcomes of Early Versus Delayed Oral Feeding After Cesarean Section in Korle-bu Teaching Hospital', '', 'UNKNOWN', 'Cesarean Section Complications', 'PROCEDURE: early feeding|PROCEDURE: delayed feeding', 'University of Ghana Medical School', '', '170.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH', '2017-02-23', '2017-08-20']\n['NCT03723395', 'A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib', '', 'COMPLETED', 'Drug-drug Interaction', 'DRUG: tucatinib|DRUG: itraconazole|DRUG: rifampin|DRUG: gemfibrozil|DRUG: repaglinide|DRUG: tolbutamide|DRUG: midazolam|DRUG: digoxin', 'Seagen Inc.', '', '116.0', 'INDUSTRY', 'INTERVENTIONAL', 'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT', '2018-09-17', '2018-12-28']\n['NCT04080895', 'Pharmacokinetic Study of Artemether-lumefantrine and Amodiaquine in Healthy Subjects', 'ALAQ', 'RECRUITING', 'Pharmacokinetic|Healthy|Drug Combination', 'DRUG: Artemether-lumefantrine|DRUG: Amodiaquine|DRUG: Artemether-lumefantrine|DRUG: Artemether-lumefantrine + Amodiaquine', 'University of Oxford', 'Mahidol University|Mahidol Oxford Tropical Medicine Research Unit', '16.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT', '2022-11-01', '2023-08-31']\n['NCT03049995', 'Stress Echo 2020 - The International Stress Echo Study', 'SE2020', 'UNKNOWN', 'Coronary Artery Disease|Heart Failure|Hypertrophic Cardiomyopathy|Aortic Valve Disease|Athletes Heart|Tetralogy of Fallot|Pulmonary Arterial Hypertension', 'PROCEDURE: Left ventricular contractile reserve SE|PROCEDURE: B-lines SE|PROCEDURE: Left ventricular outflow tract gradient SE|PROCEDURE: Diastolic function SE|PROCEDURE: Mitral regurgitation SE|PROCEDURE: Pulmonary hemodynamics SE|PROCEDURE: Coronary flow reserve SE', 'Fatebenefratelli Hospital', \"Institute of Clinical Physiology, CNR, Pisa,Italy|Salerno Hospital, Italy|Monaldi Hospital, Napoli, Italy|University of Pisa, Italy|San Luca Hospital, Lucca, Italy|Careggi University Hospital, Florence, Italy|Federico II University|San Carlo Public Hospital, Potenza, Italy|Royal Brompton & Harefield NHS Foundation Trust|Ospedale dell'Angelo, Venezia-Mestre|University of Parma|Hospital Clinics, Trieste, Italy|Federal University of Rio Grande do Sul|Hospital San José, Criciuma, Brasil|Hospital San Vicente de Paulo, Passo Fundo, Brasil|University of Belgrade|University of Szeged, Hungary|Elisabeth Hospital, Hodmezovasarhely, Hungary|Sandro Pertini Hospital, Rome, Italy|Hospital Clinics, Bari, Italy|Ospedale Nottola, Siena, Italy|University of Catania, Italy|Medika Cardiocenter, Saint Petersburg, Russian Federation|Acibadem City Clinic Tokuda Hospital|Investigaciones Medicas, Buenos Aires, Argentina|Tomsk National Research Scientific Centre of Russian Academy of Sciences, Tomsk, Russian Federation|Instituto Nacional de Cardiología Mexico City, Mexico|Hamad Medical Corporation, Heart Hospital -Doha-Qatar\", '300.0', 'OTHER', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2016-11', '2021-12']\n['NCT06073795', 'Ultrasongraphy Versus Fluoroscopy in Lumber Sympathetic Block in Chronic Lower Limb Ischemia', '', 'NOT_YET_RECRUITING', 'L L Ischemia', 'PROCEDURE: sympathetic block', 'Assiut University', '', '60.0', 'OTHER', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2023-11-01', '2025-12-01']\n['NCT04564495', 'Home Based Tele-exercise for People With Chronic Neurological Impairments', 'Telex', 'ACTIVE_NOT_RECRUITING', 'Neurologic Disorder|Stroke|Spinal Cord Injuries|Cerebral Palsy|Hemiplegia|Hemiparesis|Multiple Sclerosis|Parkinson Disease|Trauma, Brain|Transverse Myelitis|Friedreich Ataxia', 'BEHAVIORAL: Seated exercise', 'Burke Medical Research Institute', '', '60.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT', '2021-01-22', '2024-12-31']\n['NCT01811095', 'A Randomized Controlled Trial of a Robotic Simulation Curriculum to Teach Robotic Suturing', '', 'COMPLETED', 'Neoplasms', 'OTHER: Training', 'McGill University', '', '27.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: ', '2013-03', '2013-06']\n['NCT04470895', 'Impact of Drugs on the Risk of Falls in the Fracture Department of the Paris Saint-Joseph Hospital Group', '', 'WITHDRAWN', 'Fracture|Fall', 'DIAGNOSTIC_TEST: Failure Track patients analysis', 'Fondation Hôpital Saint-Joseph', '', '0.0', 'OTHER', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2021-09-24', '2021-09-24']\n['NCT04877795', 'Copeptin and HFABP in Cardiac Surgery', 'PRACTICE', 'UNKNOWN', 'Coronary Artery Disease|Valvular Heart Disease', 'DIAGNOSTIC_TEST: Blood sampling', 'Heinrich-Heine University, Duesseldorf', '', '700.0', 'OTHER', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2021-04-01', '2023-06-30']\n['NCT00804895', 'Cluster Headache Cortivazol Injection (CHCI)', 'CHCI', 'COMPLETED', 'Cluster Headache', 'DRUG: ALTIM, cortivazol injections|DRUG: PROAMP, subcutaneous serum physiological saline|DRUG: Verapamil', 'Assistance Publique - Hôpitaux de Paris', '', '43.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT', '2008-12', '2009-10']\n['NCT03053895', 'Bedside Versus Operating Room Burr-Hole Drainage of Chronic Subdural Hematoma (DECIDE)', 'DECIDE', 'UNKNOWN', 'Chronic Subdural Hematoma', 'PROCEDURE: CSDH - Bedside twist drill technique|PROCEDURE: CSDH - Operating Room Burr-hole technique', 'Hamilton Health Sciences Corporation', '', '486.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT', '2017-04-01', '2020-02-28']\n['NCT02782195', 'Evaluation of Gut Absorption Rate of Glucose After a Large Evening Meal in Type 1 Diabetes', '', 'COMPLETED', 'Type 1 Diabetes', '', 'University of Cambridge', 'Cambridge University Hospitals NHS Foundation Trust', '16.0', 'OTHER', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2008-11', '2011-06']\n['NCT00843895', 'Multicenter Prospective Evaluation of the Incidence and Serotyes of Invasive Pneumoccocal Disease (IPD) Among Children Below 5 Years', 'Pneumococci', 'UNKNOWN', 'Pneumococcal Disease', 'BIOLOGICAL: pneumococcal conjugate vaccine(prevenar)', 'King Saud University', '', '400.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SCREENING', '2009-03', '2009-12']\n['NCT05393895', 'An Evaluation of the Safety of CSF-1 in Presbyopic Subjects', '', 'COMPLETED', 'Presbyopia', 'DRUG: CSF-1|DRUG: Vehicle', 'Orasis Pharmaceuticals Ltd.', '', '178.0', 'INDUSTRY', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT', '2022-04-22', '2022-12-01']\n['NCT00145795', 'A Research Study to See if a Change in Therapy for HIV Infection Can Improve the Immune Response to Treatment', '', 'COMPLETED', 'HIV Infections', 'DRUG: Kaletra + Current Dual NRTI Backbone|DRUG: Current Regimen', 'University of Chicago', 'Abbott', '20.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT', '2004-04', '2009-12']\n['NCT06182995', 'Anticipating Decline and Providing Therapy', 'ADAPT', 'NOT_YET_RECRUITING', 'Cognitive Impairment|Dementia|Post ICU Syndrome|Critical Illness|Cognitive Impairment, Mild', 'BEHAVIORAL: Usual Care post-Intensive Care Unit (ICU)|BEHAVIORAL: Anticipating Decline and Providing Therapy (ADAPT)', 'Wake Forest University Health Sciences', 'National Institute on Aging (NIA)', '120.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE', '2024-03', '2027-03']\n['NCT04061395', 'Guselkumab for Hidradenitis Suppurativa, a Mode of Action Study.', 'HiGUS', 'UNKNOWN', 'Hidradenitis Suppurativa', 'BIOLOGICAL: Guselkumab', 'Barbara Horváth, Principal Investigator', 'Janssen-Cilag Ltd.', '20.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER', '2019-09', '2020-12']\n['NCT04114695', 'Aortic Calcification and Central Blood Pressure in Patients With Chronic Kidney Disease', 'ACCEPT', 'COMPLETED', 'Arterial Calcification|Kidney Diseases|Coronary Artery Disease|Aortic Calcification|Stroke|Vascular Diseases|Vascular Calcification', '', 'Central Jutland Regional Hospital', '', '185.0', 'OTHER', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2019-10-15', '2022-01-01']\n['NCT01170195', 'Effectiveness of Licorice Extract Dietary Supplement on the Treatment of Postmenopausal Symptoms', '', 'UNKNOWN', 'Postmenopausal Symptoms|Vaginal Dryness', 'DIETARY_SUPPLEMENT: Calmera-Licorice Root Extract (Licogen)', 'F&C Licorice Ltd', '', '120.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT', '2010-09', '2011-09']\n['NCT05409495', 'Titanium-prepared Platelet-rich Fibrin in Periodontal Regeneration', '', 'COMPLETED', 'Platelet-Rich Fibrin', 'PROCEDURE: periodontal surgical procedure (open flap debridement)|PROCEDURE: periodontal surgical procedure (OFD +autogenous Titanium-prepared platelet-rich fibrin (OFD+ T-PRF))', 'Ataturk University', '', '20.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT', '2021-04-01', '2022-02-15']\n['NCT05360095', 'Comparing Game Facilitated Interactivity to Genetic Counseling for Prenatal Screening Education', '', 'RECRUITING', 'Genetic Counseling|Shared Decision Making|Pregnancy|Genetic Testing|Prenatal Disorder', 'BEHAVIORAL: Meaning of Screening|BEHAVIORAL: Genetic Counseling|BEHAVIORAL: Usual Care', 'Erin Rothwell', 'National Human Genome Research Institute (NHGRI)', '1125.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH', '2023-03-07', '2025-12']\n['NCT02574195', 'Evolution of Effectiveness of Diabetes Medical Care in Russia', '', 'COMPLETED', 'Diabetes Mellitus, Type 2|Diabetes Mellitus, Type 1', '', 'Endocrinology Research Centre, Moscow', '', '599.0', 'OTHER_GOV', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2015-08', '2015-10']\n['NCT02975895', 'Outcome of Different IOLs in Patients With and Without Uveitis', '', 'COMPLETED', 'Uveitis|Cataract|Inflammation|Posterior Capsule Opacification', 'DEVICE: Hydrophobic IOL: Vivinex (HOYA)|DEVICE: Hydrophilic IOL: INCISE (Bausch+Lomb)', 'Vastra Gotaland Region', '', '56.0', 'OTHER_GOV', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT', '2016-12-30', '2022-03-17']\n['NCT03332095', 'Evaluating the Pharmacokinetics, Safety, and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents', '', 'COMPLETED', 'HIV Infections', 'DRUG: Doravirine (DOR)|DRUG: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF)|DRUG: Antiretroviral (ARV) medications', 'National Institute of Allergy and Infectious Diseases (NIAID)', '', '55.0', 'NIH', 'INTERVENTIONAL', 'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT', '2018-07-02', '2022-05-25']\n['NCT05191095', 'The Accuracy of Human Endoscopic Detection of Submucosal Invasive Cancer in Colorectal Polyps', '', 'COMPLETED', 'Colorectal Polyp', '', 'University Hospital, Ghent', '', '82.0', 'OTHER', 'OBSERVATIONAL', 'Observational Model: |Time Perspective: p', '2021-03-01', '2021-06-01']\n['NCT01388595', 'Fluticasone and Salmeterol in Allergic Rhinitis', '', 'COMPLETED', 'Allergic Rhinitis', 'DRUG: FLUTICASONE PROPRIONATE|DRUG: Salmeterol|DRUG: PLACEBO', 'University of Dundee', '', '23.0', 'OTHER', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT', '2006-11', '2010-10']\n['NCT00382395', 'SOLX Gold Shunt Versus Control Implant: Randomized Trial for Refractory Glaucoma', '', 'SUSPENDED', 'Glaucoma|Glaucoma, Open Angle', 'DEVICE: SOLX Gold Shunt GMS-plus|DEVICE: Ahmed FP7 Glaucoma Valve', 'SOLX, Inc.', '', '180.0', 'INDUSTRY', 'INTERVENTIONAL', 'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT', '2005-11', '2017-07']\n"
     ]
    }
   ],
   "source": [
    "from pyspark.sql import Row\n",
    "janikhanrdd = sc.textFile('/FileStore/tables/pharma.csv/pharma.csv')\n",
    "fieldsRDD = janikhanrdd.map(lambda line: line.split(','))\n",
    "cleanpharmaRDD = fieldsRDD.map(lambda fields: [field.replace('\"', '') for field in fields])\n",
    "cleanedpharmaData = cleanpharmaRDD.collect()\n",
    "for row in cleanedData:\n",
    "    print(row)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "a2a1b8e4-8bef-4ab8-915a-f0d2d4002977",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "+--------------------+--------------------+--------------------+------------------------+---------------------------------------------------------+------------+------------+-------------+---------------+--------------------+--------------------+--------------------+--------------------+--------------------+--------------------+---------------------+--------------------+--------------------+-----------------------------+--------------------+--------------------+--------------------+----------+-----------+--------------------+-----------------+--------------------+--------------------+--------------------+---------------------------+------------------------+---------------------------+---------------+---------------+\n|             Company|      Parent_Company|      Penalty_Amount|Subtraction_From_Penalty|Penalty_Amount_Adjusted_For_Eliminating_Multiple_Counting|Penalty_Year|Penalty_Date|Offense_Group|Primary_Offense|   Secondary_Offense|         Description| Level_of_Government|         Action_Type|              Agency|      Civil/Criminal|Prosecution_Agreement|               Court|             Case_ID|Private_Litigation_Case_Title|  Lawsuit_Resolution|      Facility_State|                City|   Address|        Zip|          NAICS_Code|NAICS_Translation|HQ_Country_of_Parent|  HQ_State_of_Parent| Ownership_Structure|Parent_Company_Stock_Ticker|Major_Industry_of_Parent|Specific_Industry_of_Parent|    Info_Source|          Notes|\n+--------------------+--------------------+--------------------+------------------------+---------------------------------------------------------+------------+------------+-------------+---------------+--------------------+--------------------+--------------------+--------------------+--------------------+--------------------+---------------------+--------------------+--------------------+-----------------------------+--------------------+--------------------+--------------------+----------+-----------+--------------------+-----------------+--------------------+--------------------+--------------------+---------------------------+------------------------+---------------------------+---------------+---------------+\n|             Company|      Parent_Company|      Penalty_Amount|    Subtraction_From_...|                                     Penalty_Amount_Ad...|Penalty_Year|Penalty_Date|Offense_Group|Primary_Offense|   Secondary_Offense|         Description| Level_of_Government|         Action_Type|              Agency|      Civil/Criminal| Prosecution_Agree...|               Court|             Case_ID|         Private_Litigatio...|  Lawsuit_Resolution|      Facility_State|                City|   Address|        Zip|          NAICS_Code|NAICS_Translation|HQ_Country_of_Parent|  HQ_State_of_Parent| Ownership_Structure|       Parent_Company_St...|    Major_Industry_of...|       Specific_Industry...|    Info_Source|          Notes|\n| Abbott Laboratories| Abbott Laboratories|                  $5|                     475|                                                      000|          $0|          $5|          475|            000|                2013|            20131227|government-contra...|False Claims Act ...|kickbacks and bri...|Abbott Laboratori...|  biliary and peri...|             federal|       agency action|         Justice Departmen...|               civil|                    |                    |          |           |                    |                 |                    |                    |                    |                           |                        |                        USA|       Illinois|publicly traded|\n|Abbott Laboratori...|              AbbVie|                  $1|                     500|                                                      000|         000|          $0|           $1|            500|                 000|                 000|                2012|            20120507|healthcare-relate...|off-label or unap...|                     |Global Health Car...|             federal|                agency action|Food and Drug Adm...|  civil and criminal|                    |          |           |                    |                 |                    |                    |                    |                           |                        |                           |            USA|       Illinois|\n|Abbott Laboratori...|              AbbVie|                $126|                     500|                                                      000|          $0|        $126|          500|            000|                2010|            20101207|government-contra...|False Claims Act ...|                    |Abbott Laboratori...|  B. Braun Medical...| that they engage...|             federal|                agency action|Justice Departmen...|               civil|                    |          |           |                    |                 |                    |                    |                    |                           |                        |                           |            USA|       Illinois|\n|Abbott Laboratori...|                Inc.| Abbott Laboratories|                     $49|                                                      045|          $0|         $49|          045|           2009|            20090305|employment-relate...|wage and hour vio...|Fair Labor Standa...|                    |             federal|        agency action|Labor Department ...|               civil|                             |                    |             1527129|                    |          |Puerto Rico|            San Juan|                 |                    |              423450|     423450: Medical|                     Dental|     and Hospital Equ...|                        USA|       Illinois|publicly traded|\n|      Acclarent Inc.|   Johnson & Johnson|                 $18|                     000|                                                      000|          $0|         $18|          000|            000|                2016|            20160722|government-contra...|False Claims Act ...|                    |California-based ...|  a subsidiary of ...| agreed to pay $1...|             federal|                agency action|Justice Departmen...|               civil|                    |          |           |                    |                 |                    |                    |                    |                           |                        |                           |            USA|     New Jersey|\n|Advanced Medical ...| Abbott Laboratories|                 $16|                     800|                                                       $0|         $16|         800|         2004|       20040412|employment-relate...|labor relations v...|                    |back pay award in...|             federal|       agency action| National Labor Re...|               civil|                    |                             |     21-CA-36104-001|                    |                    |California|     Irvine|                    |            92606|              333314|333314: Optical I...|                 USA|                   Illinois|         publicly traded|                        ABT|pharmaceuticals|pharmaceuticals|\n|Advanced Neuromod...|                Inc.| Abbott Laboratories|                      $2|                                                      950|         000|          $0|           $2|            950|                 000|                2007|            20070702|healthcare-relate...|HHS civil monetar...|kickbacks and bri...| The HHS Inspector...|                Inc.|  a medical devic...|          agreed to pay $2...|             federal|       agency action|Health & Human Se...|     civil|           |                    |                 |                    |                    |                    |                           |                        |                           |               |               |\n|Advanced Steriliz...|   Johnson & Johnson|                $136|                     800|                                                       $0|        $136|         800|         2014|       20140520|environment-relat...|environmental vio...|                    |The U.S. Environm...|      Calif. company| Advanced Sterili...|  has agreed to pa...|800 penalty for t...|             federal|                agency action|Environmental Pro...|               civil|                    |          |           |                    |                 |          California|              Irvine|                    |                           |                        |                           |            USA|     New Jersey|\n|Advanced Steriliz...| a division of Et...|   Johnson & Johnson|                      $1|                                                      200|         000|          $0|           $1|            200|                 000|                2013|            20131204|safety-related of...|drug or medical e...|                    | Settlement of a c...| a division of Et...| a Johnson & John...|          and two of ASP's...|             federal|       agency action|Food and Drug Adm...|     civil|           |                    |                 |                    |                    |          California|                     Irvine|                        |                           |               |               |\n|Alere San Diego Inc.| Abbott Laboratories|                 $10|                     572|                                                       $0|         $10|         572|         2017|       20170309|employment-relate...|wage and hour vio...|Fair Labor Standa...|                    |             federal|       agency action| Labor Department ...|               civil|                    |                             |             1813371|                    |                    |California|     Pomona|828 Towne Center Dr.|            91767|                    |                    |                 USA|                   Illinois|         publicly traded|                        ABT|pharmaceuticals|pharmaceuticals|\n|       Allergan Inc.|              AbbVie|                $600|                     000|                                                      000|          $0|        $600|          000|            000|                2010|            20100901|healthcare-relate...|off-label or unap...|                    |American pharmace...|    Botox Therapeutic| for uses not app...|             federal|                agency action|Food and Drug Adm...|  civil and criminal|                    |          |           |                    |                 |                    |                    |                    |                           |                        |                           |            USA|       Illinois|\n|       Allergan Inc.|              AbbVie|                 $15|                     000|                                                      000|          $0|         $15|          000|            000|                2017|            20170117|  financial offenses|investor protecti...|                    |Allergan Inc. adm...|              federal|       agency action|Securities and Ex...|                        civil|                    |                    |                    |          |           |                    |                 |                    |                    |                    |                           |                     USA|                   Illinois|publicly traded|           ABBV|\n|       Alpharma Inc.|              Pfizer|                 $42|                     500|                                                      000|          $0|         $42|          500|            000|                2010|            20100316|government-contra...|False Claims Act ...|kickbacks and bri...|Alpharma Inc. agr...|  2000 and Decembe...| 2008 Alpharma pa...| and made misrepr...|                      federal|       agency action|Justice Departmen...|               civil|          |           |                    |                 |                    |                    |                    |                           |                        |                           |               |            USA|\n|            Alpharma|                Inc.|              Pfizer|                      $2|                                                      500|         000|          $0|           $2|            500|                 000|                2004|            20040812|competition-relat...|price-fixing or a...|consumer protecti...| Generic drug manu...|             federal|       agency action|         Federal Trade Com...|               civil|                    |                    |          |           |                    |                 |                    |                    |                    |                           |                        |                        USA|       New York|publicly traded|\n|American Pharmace...|                Inc.|Bristol-Myers Squibb|                    $160|                                                      203|          $0|        $160|          203|           2004|            20041226|employment-relate...|wage and hour vio...|Fair Labor Standa...|                    |             federal|        agency action|Labor Department ...|               civil|                             |                    |             1379241|                    |          |   New York|        Grand Island|                 |               14072|               32541|32541: Pharmaceut...|                        USA|                New York|            publicly traded|            BMY|pharmaceuticals|\n|          Amgen Inc.|               Amgen|                $762|                     000|                                                      000|          $0|        $762|          000|            000|                2012|            20121219|healthcare-relate...|off-label or unap...|                    |U.S. District Jud...|  Jr. accepted a g...|             federal|       agency action|         Food and Drug Adm...|  civil and criminal|                    |                    |          |           |                    |                 |                    |                    |                    |                           |                        |                        USA|     California|publicly traded|\n|          Amgen Inc.|               Amgen|                 $24|                     900|                                                      000|          $0|         $24|          900|            000|                2013|            20130416|government-contra...|False Claims Act ...|kickbacks and bri...|Amgen Inc. agreed...|  PharMerica Corpo...|             federal|       agency action|         Justice Departmen...|               civil|                    |                    |          |           |                    |                 |                    |                    |                    |                           |                        |                        USA|     California|publicly traded|\n|               Amgen|                Inc.|               Amgen|                     $40|                                                      000|          $0|         $40|          000|           2011|            20110302|employment-relate...|labor relations v...|                    |back pay award in...|             federal|        agency action|National Labor Re...|               civil|                             |                    |     14-CA-30273-001|                    |          |   Missouri|           St. Louis|                 |               63130|              541720|541720: Research ...|                        USA|              California|            publicly traded|           AMGN|pharmaceuticals|\n|Amneal Pharmaceut...|                 LLC|Amneal Pharmaceut...|                     $99|                                                      000|          $0|         $99|          000|           2015|            20150930|employment-relate...|employment discri...|                    |                    |             federal|        agency action|Office of Federal...|               civil|                             |                    |                    |                    |          |           |                    |                 |                    |                    |                    |                        USA|              New Jersey|            publicly traded|           AMRX|pharmaceuticals|\n+--------------------+--------------------+--------------------+------------------------+---------------------------------------------------------+------------+------------+-------------+---------------+--------------------+--------------------+--------------------+--------------------+--------------------+--------------------+---------------------+--------------------+--------------------+-----------------------------+--------------------+--------------------+--------------------+----------+-----------+--------------------+-----------------+--------------------+--------------------+--------------------+---------------------------+------------------------+---------------------------+---------------+---------------+\nonly showing top 20 rows\n\n"
     ]
    }
   ],
   "source": [
    "from pyspark.sql import Row\n",
    "\n",
    "# Define the schema \n",
    "schema = StructType([\n",
    "    StructField(\"Company\", StringType(), True),\n",
    "    StructField(\"Parent_Company\", StringType(), True),\n",
    "    StructField(\"Penalty_Amount\", StringType(), True),\n",
    "    StructField(\"Subtraction_From_Penalty\", StringType(), True),\n",
    "    StructField(\"Penalty_Amount_Adjusted_For_Eliminating_Multiple_Counting\", StringType(), True),\n",
    "    StructField(\"Penalty_Year\", StringType(), True),\n",
    "    StructField(\"Penalty_Date\", StringType(), True),\n",
    "    StructField(\"Offense_Group\", StringType(), True),\n",
    "    StructField(\"Primary_Offense\", StringType(), True),\n",
    "    StructField(\"Secondary_Offense\", StringType(), True),\n",
    "    StructField(\"Description\", StringType(), True),\n",
    "    StructField(\"Level_of_Government\", StringType(), True),\n",
    "    StructField(\"Action_Type\", StringType(), True),\n",
    "    StructField(\"Agency\", StringType(), True),\n",
    "    StructField(\"Civil/Criminal\", StringType(), True),\n",
    "    StructField(\"Prosecution_Agreement\", StringType(), True),\n",
    "    StructField(\"Court\", StringType(), True),\n",
    "    StructField(\"Case_ID\", StringType(), True),\n",
    "    StructField(\"Private_Litigation_Case_Title\", StringType(), True),\n",
    "    StructField(\"Lawsuit_Resolution\", StringType(), True),\n",
    "    StructField(\"Facility_State\", StringType(), True),\n",
    "    StructField(\"City\", StringType(), True),\n",
    "    StructField(\"Address\", StringType(), True),\n",
    "    StructField(\"Zip\", StringType(), True),\n",
    "    StructField(\"NAICS_Code\", StringType(), True),\n",
    "    StructField(\"NAICS_Translation\", StringType(), True),\n",
    "    StructField(\"HQ_Country_of_Parent\", StringType(), True),\n",
    "    StructField(\"HQ_State_of_Parent\", StringType(), True),\n",
    "    StructField(\"Ownership_Structure\", StringType(), True),\n",
    "    StructField(\"Parent_Company_Stock_Ticker\", StringType(), True),\n",
    "    StructField(\"Major_Industry_of_Parent\", StringType(), True),\n",
    "    StructField(\"Specific_Industry_of_Parent\", StringType(), True),\n",
    "    StructField(\"Info_Source\", StringType(), True),\n",
    "    StructField(\"Notes\", StringType(), True)\n",
    "])\n",
    "\n",
    "def create_row(row):\n",
    "    if len(row) == 34:\n",
    "        return Row(*row)\n",
    "    elif len(row) > 34:\n",
    "        return Row(*row[:34])\n",
    "    else:\n",
    "        return None\n",
    "\n",
    "pharmadf = cleanpharmaRDD.map(create_row).filter(lambda x: x is not None).toDF(schema)\n",
    "\n",
    "# View the DataFrame\n",
    "pharmadf.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "7a62d420-c9ef-4372-ad46-0b0865be0529",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "+---------------+------+\n|           Type| count|\n+---------------+------+\n| INTERVENTIONAL|371382|\n|  OBSERVATIONAL|110221|\n|EXPANDED_ACCESS|   928|\n+---------------+------+\nonly showing top 3 rows\n\n"
     ]
    }
   ],
   "source": [
    "#question # 2\n",
    "cleandf.groupBy(\"Type\").count().orderBy(\"count\" , ascending=False).show(3)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "820833d2-4c88-4f19-a29d-354a25a44643",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "+-------------+-----+\n|   Conditions|count|\n+-------------+-----+\n|      Healthy| 9731|\n|Breast Cancer| 7502|\n|      Obesity| 6549|\n|       Stroke| 4072|\n| Hypertension| 4020|\n+-------------+-----+\nonly showing top 5 rows\n\n"
     ]
    }
   ],
   "source": [
    "#question 3\n",
    "from pyspark.sql.functions import *\n",
    "df1 = cleandf.withColumn(\"Conditions\" , explode(split(cleandf[\"Conditions\"] , \"\\|\")))\n",
    "df2 = df1.groupBy(\"Conditions\").count().orderBy(desc(\"count\")).show(5)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "76a9c0bd-df90-4763-bc2f-73d5d8bb7f72",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "+--------------------+-----+\n|             Sponsor|count|\n+--------------------+-----+\n|National Cancer I...| 3410|\n|   Assiut University| 3335|\n|    Cairo University| 3023|\n|Assistance Publiq...| 2951|\n|         Mayo Clinic| 2766|\n|M.D. Anderson Can...| 2702|\n|National Institut...| 2340|\n|Massachusetts Gen...| 2263|\n|National Taiwan U...| 2181|\n|Merck Sharp & Doh...| 1896|\n+--------------------+-----+\nonly showing top 10 rows\n\nNone\n"
     ]
    }
   ],
   "source": [
    "#question 4\n",
    "from pyspark.sql import functions as F\n",
    "non_pharma_sponsors_df = cleandf.filter(~F.col(\"Sponsor\").isin(pharmadf.select('Company').distinct().rdd.flatMap(lambda x: x).collect()))\n",
    "sponsor_counts_df = non_pharma_sponsors_df.groupBy(\"Sponsor\").count().orderBy(F.desc(\"count\")).show(10)\n",
    "top_10_sponsors_df = print(sponsor_counts_df)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "0ef2e7e8-3007-4f3c-95f3-954688164f0a",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "+----------------+-----+\n|Completion_Month|count|\n+----------------+-----+\n|               1| 1494|\n|               2| 1272|\n|               3| 1552|\n|               4| 1324|\n|               5| 1415|\n|               6| 1619|\n|               7| 1360|\n|               8| 1230|\n|               9| 1152|\n|              10| 1058|\n|              11|  909|\n|              12| 1082|\n+----------------+-----+\n\n"
     ]
    }
   ],
   "source": [
    "from pyspark.sql.functions import month, year\n",
    "\n",
    "Task5 = cleandf.filter(cleandf[\"Status\"] == \"COMPLETED\") \\\n",
    "    .filter(year(\"Completion\") == 2023)\n",
    "Task5 = Task5.withColumn(\"Completion_Month\", month(\"Completion\"))\n",
    "month = Task5.groupBy(\"Completion_Month\").count().orderBy(\"Completion_Month\")\n",
    "month.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "fb9a366b-b709-4283-911d-e68434da5aec",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "display_data",
     "data": {
      "image/png": "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\n"
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "addedWidgets": {},
       "arguments": {},
       "data": "data:image/png;base64,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\n",
       "datasetInfos": [],
       "metadata": {},
       "removedWidgets": [],
       "type": "image"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "from pyspark.sql.functions import month, year\n",
    "import matplotlib.pyplot as plt\n",
    "\n",
    "completed_studies_2023 = cleandf.filter(cleandf[\"Status\"] == \"COMPLETED\") \\\n",
    "    .filter(year(\"Completion\") == 2023)\n",
    "completed_studies_2023 = completed_studies_2023.withColumn(\"Completion_Month\", month(\"Completion\"))\n",
    "monthly_counts = completed_studies_2023.groupBy(\"Completion_Month\").count().orderBy(\"Completion_Month\")\n",
    "\n",
    "monthly_counts_list = monthly_counts.collect()\n",
    "\n",
    "months = [row[0] for row in monthly_counts_list]\n",
    "counts = [row[1] for row in monthly_counts_list]\n",
    "\n",
    "plt.figure(figsize=(10, 6))\n",
    "plt.plot(months, counts)\n",
    "plt.xlabel('Month')\n",
    "plt.ylabel('Number of Completed Studies')\n",
    "plt.title('Completed Studies by Month in 2023')\n",
    "plt.xticks(rotation=90)\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {},
     "inputWidgets": {},
     "nuid": "32abb220-d4f8-4122-8a5e-16a9bd7860cb",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "application/vnd.databricks.v1+notebook": {
   "dashboards": [],
   "language": "python",
   "notebookMetadata": {
    "mostRecentlyExecutedCommandWithImplicitDF": {
     "commandId": 1571985923468400,
     "dataframes": [
      "_sqldf"
     ]
    },
    "pythonIndentUnit": 4
   },
   "notebookName": "Abdul_Manan_Abbasi_ Data Frame",
   "widgets": {}
  }
 },
 "nbformat": 4,
 "nbformat_minor": 0
}
